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I. Introduction 
 
1.1. Genetic basis of cancer 
Worldwide, between 100 and 350 of each 100,000 people die of cancer each year (Lodish 
et al., 2003). Cancer is due to failures of the mechanisms that usually control the growth 
and proliferation of cells. During normal development and throughout adult life, intricate 
genetic control systems regulate the balance between cell birth and death in response to 
growth signals, growth-inhibiting signals, and death signals.  
The loss of cellular regulation that gives rise to most or all cases of cancer are due to 
genetic damage. Mutations in two broad classes of genes have been implicated in the 
onset of cancer: proto-oncogenes and tumor suppressor genes (Lodish et al., 2003). 
Proto-oncogenes are activated to become oncogenes by mutations that cause the gene to 
be excessively active in growth promotion, which is either due to increased gene 
expression or production of a hyperactive product. Tumor suppressor genes normally 
restrain growth, so damage to them allows inappropriate growth. Many of the genes in 
both classes encode proteins that help regulate cell birth (i.e., entry into and progression 
through the cell cycle) or cell death by apoptosis; others encode proteins that participate 
in repairing damaged DNA. Conversion, or activation, of a proto-oncogene into an 
oncogene generally involves a gain-of-function mutation. At least four mechanisms can 
produce oncogenes from the corresponding proto-oncogenes: 
Point mutations (i.e., change in a single base pair) in proto-oncogenes that resuls in 
constitutively active protein products 
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Chromosomal translocations which fuse two genes together to produce a hybrid gene 
encoding a chimeric protein whose activity, unlike that of the parent proteins, often is 
constitutive 
Chromosomal translocations which bring a growth regulatory gene under the control of 
a different promoter that causes inappropriate expression of the gene 
Amplification (i.e., abnormal DNA replication) of a DNA segment including a proto-
oncogene, so that numerous copies exist, leading to overproduction of the encoded 
protein 
An oncogene formed by either of the first two mechanisms encodes an “oncoprotein” 
that differs from the normal protein encoded by the corresponding proto-oncogene. In 
contrast, the other two mechanisms generate oncogenes whose protein products are 
identical with the normal proteins; their oncogenic effect is due to production at higher 
than normal levels or their presence in cells where they normally are not produced 
(Lodish et al., 2003). 
1.2. Chromosomal Translocations 
1.2.1. Definition 
Translocation (trans = across; location = place) is the term used to describe a 
rearrangement of chromosome material involving two or more chromosomes.  
1.2.2. Types of chromosomal translocations 
Two types of chromosomal translocations exist: 
1. Reciprocal translocations: Reciprocal translocations are the most common type 
of translocation. These translocations can occur between any of the chromosomes 
and involve pieces of any size. Pieces of each of these chromosomes have 
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changed places and the pieces have become attached to the other chromosome. In 
this case, where there does not appear to have been any loss or gain of 
chromosome material, the translocation is described as balanced. 
2. Robertsonian translocations: Named after the American insect geneticist who 
described them, W. R. B. Robertson, Robertsonian translocations only involve 
exchanges between human chromosome numbers 13, 14, 15, 21 and 22. The 
exchange involves loss of the short arms of two chromosomes and fusion of the 
remaining two long arms at their centromeres. Robertsonian translocations can 
also occur between the two chromosomes of the same pair. 
1.2.3. Occurrence of chromosomal translocation 
Though the mechanism and reason underlying chromosomal translocations is not well 
understood, there are at least two theories (Levitan et al., 2003): 
1. Rearrangements occur at random, but selection acts to eliminate those that do not 
provide the cell with a proliferative advantage 
2. Alternatively, certain changes may occur preferentially and, thus, may be the ones 
that that are observed 
1.2.4. Causes of chromosomal translocation 
Though the cause of chromosomal rearrangement is in most cases not known exactly, one 
of the main causes is believed to be an exposure to radiation for a prolonged time period. 
Illegitimate V(D)J recombination, class switch recombination, homologous 
recombination, non-homologous end joining, and fragile sites all have potential roles in 
the production of non-random chromosomal translocations (Aplan, 2006). In addition, 
mutations in DNA repair pathways have been implicated in the production of 
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chromosomal translocations in humans, mice, and yeast (Aplan, 2006). Some breakage 
events in pre–B or pre–T cells are due to the RAG (recombination activating gene) 
proteins recognizing heptamer/nonamer-like sequences (Lieber  et al., 2008).  
1.2.5. Consequences of chromosomal translocations 
Based on the potential effects that chromosomal translocations might entail, two 
consequences are noted: 
a. enforced oncogene expression that occurs when an oncogene is subjected to a new 
chromosomal environment such as a very active promoter or enhancer element, or  
b. gene fusion between exons of two genes, whereby the two genes affected by the 
translocation form a fusion gene which gives rise to a fusion protein. 
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Figure 1.1.  Consequences of chromosomal translocations (a) enforced gene expression, (b) 
fusion gene.  
1.3. Chromosomal translocations in hematopoietic malignancies 
Chromosomal translocations, especially recurrent chromosomal translocations, are 
requently found in malignancies and play an important role in malignant transformation. 
As discussed above, translocations can lead to the juxtaposition of the coding region of a 
gene near the transcriptionally active promoter/enhancer region of another gene, hence 
leading to over-expression of the former gene (Nambiar et al., 2008). Examples of such 
events are the IgH-BCL2  and IgH-MYC  rearrangements (Korsmeyer, 1992, Rabbitts, 
(a) 
    
 
 
 
(b) 
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1991) where BCL2 and MYC show overexpression. Translocations can also result in the 
formation of a fusion gene. For instance, the t(9;22) translocation results in the fusion of 
the ABL1 gene on chromosome 9 with the BCR gene on chromosome 22, thereby forming 
the fusion gene due to the formation of a unique in-frame fusion mRNA and protein 
(Rowley, 2001, Rowley and Potter, 1976, Rowley, 1973). The BCR/ABL fusion gene is 
under the control of the BCR promoter. Table 1.1 and table 1.2 give lists of the different 
translocation events and their consequences. 
Table 1.1. Some selected chromosomal translocations involved in hematopoietic malignancies leading to altered gene expression (adapted from Nambiar et al. (2008) with some modifications). 
 
Type of 
translocation 
Affected gene Type of 
tumor 
Mechanism of 
activation 
References 
t(8;14)(q24;q32) c-myc(8q24) BL, B-ALL Relocation to IgH 
locus 
Rabbits et al., Adv Immun, 
1991. 50:119–146 
t(7;19)(q35;p13) lyl1(19p13) T-ALL Relocation to 
TCR-β locus 
Mellentin et al., Cell, 1989. 
58: 77–83 
t(1;14)(p32;q11) tal1/scl(1p32) T-ALL Relocation to 
TCR-α Locus 
Baer et al., Sem. Cancer 
Biol., 1993. 4:341–347 
t(11;14)(p15;q11) rbtn1/ttg1(11p15) T-ALL Relocation to 
TCR-δ Locus 
Boehm et al., EMBO J, 1988. 
7:385–94 
    McGuire et al., Mol. Cell. Biol, 
1989. 9:2124–32 
    Boehm et al., PNAS, USA, 
1991. 88:4367–71 
t(10;14)(q24;q11) hox11(10q24) T-ALL Relocation to 
TCR-α/β locus 
Lu et al., Genes Chr Cancer, 
1990. 2:217–22 
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    Kagan et al., PNAS, USA, 
1989. 86:4161–5 
    Zutter et al., PNAS, USA, 
1990. 87:3161–5 
t(11;14)(q13;q32) Bcl1(11q13) B-CLL Relocation to IgH 
locus 
Tsujimoto et al., Science, 
1984. 224:1403–6 
    Tsujimoto et al., Nature, 
1985. 315:340–3 
    Welzel et al., Cancer Res., 
2001. 61: 1629–1636 
t(5;14)(q31;q32) IL-3(5q31) pre-B-ALL Relocation to IgH 
locus 
Grimaldi et al., Blood, 1989. 
73:2081–2085 
    Meeker et al., Blood, 1990. 
76:285–289 
t(1;7)(p34;q34) lck(1p34) T-ALL Relocation to 
TCR-β Locus 
Tycko et al., J. Exp. Med., 
1991. 174:867–873 
t(X;14)(q28;q11) C6.1B(Xq28) T-PLL Relocation to 
TCR-α locus 
Stern et al., Oncogene, 1993. 
8:2475–2483 
t(14;21)(q11;q22) bhlhb1(21q22) pre-T-LBL Relocation to 
TCRA/D locus 
Wang et al., PNAS, 2000. 97: 
3497–3502 
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 Table 1.2. Some selected chromosomal translocations involved in hematopoietic tumors leading to gene fusions (adapted from Nambiar et al. (2008) with some modifications). 
 
Type of translocation Type of tumor Genes involved References 
t(8;21)(q22;q22) AML-M2 AML1/CBFα(21q22) and 
ETO/MTGβ(8q22) 
Ohki M, Sem. Cancer Biol., 
1993. 4:369–376 
t(15;17)(q21;q21) APL PML (15q21) and RARA 
(17q21) 
Gillard et al., Sem. Cancer 
Biol., 1993. 4:359–368 
t(8;16)(p11;p13)  AML MOZ(8p11) and 
CBP(16p13) 
Borrow J et al., Nat Genet., 
1996. 14:33–41 
t(9;22)(q34q11.2) CML/ALL BCR(22q11) and c-
ABL(9q34) 
de Klein et al., Nature, 
1982. 300:765–767 
t(11;17)(q23;q21.1) AML-M3 PLZF (11q23) and RARA 
(17q21) 
Chen et al., EMBO J., 
1993. 12:1161–1167 
t(9;11)(p22;q23) AML-M4, pre-B-ALL MLL (11q23) and AF9 
(9p22) 
Nakamura et al., PNAS, 
1993. 90: 4631–4635 
t(6;11)(q27;q23) AML-M5, ALL MLL (11q23) and AF6 
(6q27) 
Prasad et al., Cancer Res., 
1993. 53:5624–5628 
t(6;9)(p23;q34) AML-M1,M2,M4,M5 DEK (6p23) and CAN 
(9q34) 
von Lindern, Mol. Cell Biol., 
1992. 12:1687–1697 
t(16;21)(p11;q22) AML FUS(16p11) and 
ERG(21q22) 
Shimizu et al., PNAS, 
1993. 90:10280–10284 
t(16;21)(q24;q22) t-AML, MDS AML1(21q22) and  
MTG(16q24) 
Gamou T et al., Blood, 
1998. 91:4028–4037. 
t(12;22)(p13;q11–12) MDS ETV6(12p13)/TEL and 
MN1(22q11) 
Buijs A et al., Oncogene, 
1995. 10:1511–1519 
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t(12;21)(p12–13;q22) Pre-B-ALL TEL(12p12) and 
AML1(21q22) 
Romana et al., Blood, 
1995. 86:4263–4269 
Golub et al., Proc. Natl. 
Acad. Sci. USA, 1995. 92: 
4917-4921 
t(4;11)(q21;q23) Pre-B-ALL MLL(11q23) and 
AF4(4q21) 
Djabali et al., Nature 
Genet., 1992. 2: 113–118 
   Gu et al., Cell, 1992. 
71:701–708 
t(11;19)(q23;p13) Pre-B-ALL, T-ALL MLL(11q23) and 
ENL(19p13) 
Tkachuk et al., Cell, 1992. 
71:691–700 
   Yamamoto et al., 
Oncogene, 1993. 8: 2617–
2625 
t(2;5)(p23;q35) ALCL (NHL) NPM (5q35) and ALK 
(2p23) 
Morris et al., Science, 
1994. 263:1281–1284 
inv(16)(p13q22) AML, MDS at times MYH11 Bernard et al.,Leukemia, 
1989. 3 (10) : 740-745. 
Campbell et al., 1991, 
Genes, chromosomes & 
cancer.3 (1) : 55-61. 
 
t(10;11)(p12;q14) pre-T-ALL, AML CALM (11q14) and 
AF10(10p12) 
Dreyling et al., Proc. Natl. 
Acad. Sci. USA. 1996. 93, 
4804-4809. 
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1.4. CALM/AF10 
The t(10;11)(p12;q14) is a recurring chromosomal translocation that is found in acute 
myeloid and acute lymphoblastic leukemia as well as in malignant lymphoma (Dreyling 
et al., 1996). This translocation results in the fusion of AF10 (Chaplin et al., 1995), a 
putative zinc finger transcription factor containing an N-terminal LAP/PHD zinc finger 
motif, a nuclear localization signal, an AT-hook domain, and a leucine zipper and with 
the CALM gene (Clathrin assembly protein lymphoid myeloid leukemia gene) that 
encodes a clathrin assembly protein.  
(Linder et al., 2000, Saha et al., 1995) have identified a novel protein-protein interaction 
motif in the AF10 protein comprising the extended LAP/PHD-finger domain that 
mediates homo-oligomerisation of recombinant AF10 and is conserved in several 
proteins, including MLL itself. AF10 binds cruciform DNA via a specific interaction with 
an AT-hook motif and is localized to the nucleus by a defined bipartite nuclear 
localization signal in the N-terminal region (Linder et al., 2000). Furthermore, it has 
recently been shown that PHD domains interact with H3K4me3 (Li et al., 2006, Peña et 
al., 2006), potentially playing a crucial role in transcription initiation as H3K4me3 
modifications have recently been shown to be associated with gene expression (Barski et 
al., 2007).  
CALM (for Clathrin Assembly Lymphoid Myeloid; also known as PICALM) is located 
on chromosome 11q23, is ubiquitously expressed and encodes a 652 amino acid protein 
with multiple domains involved in endocytosis (Dreyling et al., 1996). These domains 
include the epsin N-terminal homology (ENTH) domain (Asp-Pro-Phe), a DPF (ASP-
Pro-Phe) motif, an NPF (Asn-Pro-Phe) motif and type I and II clathrin-binding sequences 
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(CBS I and II) (Anika Meyerholz, 2005, Tebar et al., 1999, Klebig et al., 2003). The 
predicted CALM protein is similar to the neuronal specific monomeric clathrin assembly 
protein AP180, which was first identified in coated vesicles of bovine brain (S Ahle and 
Ungewickell, 1986, Takei et al., 1996). CALM homologues have been identified in rat, 
mouse and cow. 
The CALM/AF10 fusion mRNA codes for the CALM/AF10 fusion protein which 
contains almost the complete CALM protein fused in frame to about 90% of the AF10 
protein without the N terminal two PHD zinc fingers (Dreyling et al., 1996) (See figures 
2 and 3). In the monocytic cell line U937 both the CALM/AF10 and the AF10/CALM 
fusion mRNAs can be identified (Dreyling et al., 1996).  CALM/AF10 chimeric 
transcripts (six isoforms of the CALM/AF10 fusion transcripts and five of AF10/CALM) 
were detected by RT-PCR in hematological malignancies with t(10;11)(p13;q14) in 
patient samples including ALL, AML and lymphoblastic lymphoma, and in three 
monocytic cell lines (P31/Fujioka, KP-Mo-TS and U937) (Ashihara et al., 2007, Narita et 
al., 1999). 
CALM/AF10 is highly Leukemogenic. CALM/AF10 leads to the development of an 
aggressive acute leukemia with in a murine bone marrow transplant model (Deshpande et 
al., 2006). According to Deshpande et al. (2006), all mice (n = 13) transplanted with 
highly purified GFP+ CALM/AF10 (murine stem cell virus (MSCV)-based retroviral 
construct carrying the CALM/AF10 cDNA upstream of an internal ribosomal entry site 
(IRES)-green fluorescence protein (GFP) cassette) transduced cells (median retroviral 
transduction efficiency of 5.7, range 1.2%–16.4%) with or without non-transduced helper 
Introduction 
12 
 
cells developed the disease after a median of 110 days post-transplantation (range 46–
366).  
 
 
 
 
 
 
 
 
 
Figure 1. 2. t(10;11)(p12;q14) leading to fusion of CALM and AF10. (a) the translocation event, 
arrows indicating the approximate position of translocation and gene direction (b) the genes 
involved (CALM and AF10) and their  fusion products as a consequence of t(10;11)(p12;q14). 
AF10 contains an octapeptide motif and leucine zipper domain (OM/LZ) and a plant homeo 
domain (PHD) finger. Small triangles indicate the different breaking points in AF10 and in 
CALM as observed in CALM/AF10 patients. Numbers stand for amino acid counts. 
 
(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
 Introduction 
13 
 
In a recent report, (Caudell et al., 2007) showed that 40% to 50% of the F1 generation of 
transgenic mice that express CALM/AF10 under the control of the vav promoter 
developed acute leukemia at a median age of 12 months. The transgenic mice were 
generated by cloning CALM/AF10 into the HS21/45-vav vector that uses 5′ and 3′ vav 
regulatory elements to direct expression of cDNA inserts specifically in hematopoietic 
tissues.  Caudell and co-workers also reported, based on real-time RT-PCR experiment, 
that Hoxa5, Hoxa7, Hoxa9, Hoxa10, and Meis1 were all up-regulated in hematopoietic 
tissues (bone marrow, spleen, and thymus) from clinically healthy CALM/AF10. These 
genes were also found to be up-regulated in Myeloid leukemias from CALM/AF10 mice, 
indicating that up-regulation of these genes occurs in myeloid as well as T-cell tumors 
associated with CALM/AF10 expression (Caudell et al., 2007). Hox genes encode a class 
of transcription factors called homeobox genes and are found in clusters named A, B, C, 
and D on four separate chromosomes. Expression of these proteins is spatially and 
temporally regulated during embryonic development, and they regulate gene expression, 
morphogenesis, and differentiation. They encode proteins that involved in the placement 
of hindbrain segments in the proper location along the anterior-posterior axis during 
development. Meis1 (myeloid ecotropic viral integration site 1) is also a homeobox gene 
and encodes a protein belonging to the TALE ('three amino acid loop extension') family 
of homeodomain-containing proteins. 
Caudell et al. (2007) assayed the genes Hoxa5, Hoxa7, Hoxa9, Hoxa10, and Meis1 based 
on the findings of a previous report on patient microarray study that compared 
CALM/AF10+ to CALMAF10- T-ALL (Dik et al., 2005). Dik and co-workers reported 
that their analysis showed the up-regulation of HOXA5, HOXA9, HOXA10 and BMI1 in 
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the CALM/AF10+ cases, a finding that they validated by quantitative RT-PCR by 
comparing an independent group of T-ALL to mixed lineage leukemia-translocated acute 
leukemias (MLL-t AL). The over-expression of HOXA genes was associated with 
overexpression of its cofactor MEIS1 (myeloid ecotropic viral integration site homeobox 
1) in CALM/AF10+ T-ALL, reaching levels of expression similar to those observed in 
MLL-t AL (Dik et al., 2005). Consequently, Dik et al. (2005) reported that 
CALM/AF10+ T-ALL and MLL-t AL share a specific HOXA overexpression, indicating 
they activate common oncogenic pathways.  
Furthermore, BMI1 (polycomb, ubiquitin ligase, B-lymphoma Mo-MLV integration site), 
a gene located close to AF10 breakpoint and controls cellular proliferation through 
suppression of the tumor suppressors encoded by the CDKN2A locus, was found to be 
over-expressed only in CALM/AF10+ T-ALL and not in MLL-t AL (Dik et al., 2005). 
As CDKN2A  is often deleted in T-ALL and was found to be conserved in CALM/AF10+ 
T-ALL, Dik and co-workers suggested  that decreased CDKN2A activity, as a result of 
BMI1 overexpression, contributes to leukemogenesis in CALM/AF10+ T-ALL. 
Little is known about the molecular mechanism of leukemogenesis of CALM/AF10 
(Caudell and Aplan, 2008). Recently, there has been a report that demonstrated that the 
H3K79 methyltransferase hDOT1L (DOT1-like, histone H3 methyltransferase (S. 
cerevisiae)), a gene that mediates H3K79 methylation and is associated with telomere 
silencing, meiotic checkpoint control, and DNA damage response) contributes to MLL–
AF10-mediated leukemogenesis through its interaction with AF10 (Okada et al., 2005). 
The role of DOT1L in embryonic development, genome stability and heterochromatin 
formation has very recently been shown in a report where (Jones et al., 2008) analyzed 
 Introduction 
15 
 
mouse embryonic stem (ES) derived from Dot1L mutant blastocysts and observed that 
these cells had global loss of H3K79 methylation as well as reduced levels of 
heterochromatic marks (H3K9 di-methylation and H4K20 tri-methylation) at their 
centromeres and telomeres. Jones and co-workers further noted that these changes are 
accompanied by aneuploidy, telomere elongation, and proliferation defects.  
According to Okada et al. (2005), mistargeting of hDOT1L to Hoxa9 plays an important 
role in MLL-AF10-mediated leukemogenesis and suggests that the enzymatic activity of 
hDOT1L may provide a potential target for therapeutic intervention. In another 
experiment where CALM/AF10 was knocked down in U937 cells using a vector-based 
RNA interference (RNAi) and later transplanted into NOD/SCID mice.  The same group 
found that hDOT1L contributes to CALM–AF10- mediated leukemic transformation by 
preventing nuclear export of CALM–AF10 and up-regulation of the Hoxa5 gene through 
H3K79 methylation (Okada et al., 2006). In contrast to the hypothesis put forward by Dik 
et al. (2005), Okada and co-workers demonstrated that CALM/AF10 fusion is both 
necessary and sufficient for leukemic transformation. 
Even though much is known about the CALM/AF10 fusion from patient samples and the 
leukemic potential of CALM/AF10 is well established in mouse models, the mechanisms 
that are required for CALM/AF10-mediated leukemogenesis are still poorly understood. 
The aim of this study is to identify immediate target genes of CALM/AF10 using gene 
expression profiling on an Affymetrix microarray platform with an inducible 
CALM/AF10 cell line system. Identifying early and potentially direct targets of 
CALM/AF10 will increase our understanding of the molecular mechanism of 
CALM/AF10-mediated-leukemogenesis.
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II. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
Table 2.1. List of chemicals 
 
Name of 
Reagent 
 
 
IUPAC Name 
 
Molecular 
formula 
 
Molar 
Mass 
(g/mol) 
 
Company 
Agarose (14)-3,6-anhydro-α-L-
galactopyranosyl-(13)-β-D-
galactopyranan 
 167.6 ± 7.8 
× 103 
Carl Roth® 
GmbH, 
Germany 
Aprotinin Aprotinin C284H432N84O79S7 6511.51 Sigma-
Aldrich®, 
USA 
ATP 5-(6-aminopurin-9-yl) 
-3,4-dihydroxy-oxolan-2-yl 
methoxy-hydroxy-phosphoryl 
oxy-hydroxy-phosphoryl 
oxyphosphonic acid 
C10H16N5O13P3 507.181 Invitrogen®, 
USA 
Bromophenol 
blue  
2,6-dibromo-4-[3-(3,5-dibromo-4-
hydroxyphenyl)-1,1-dioxo-3-
benzo[c]oxathiolyl]phenol 
C19H10Br4O5S 669.9607 NEB®, USA 
Chloroform Chloroform CHCl3 119.38 Carl Roth® 
GmbH, 
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 Germany 
dATP Deoxyadenosine triphosphate C10H16N5O12P3 491.181623 Invitrogen®, 
USA 
dCTP Deoxycytidine triphosphate C9H16N3O13P3 467.156923 Invitrogen®, 
USA 
DEPC 
 
Diethylpyrocarbonate C6H10O5 162.141 Invitrogen, 
USA 
dGTP Deoxyguanosine triphosphate C10H16N5O13P3 507.181023 Invitrogen®, 
USA 
DMSO dimethyl sulfoxide C2H6OS 78.13 Carl Roth® 
GmbH, 
Germany 
DTT 2S,3S)-1,4-Bis-sulfanylbutane-2,3-diol C4H10O2S2 154.26 Invitrogen®, 
USA 
dTTP Deoxythymidine-triphosphatase   Invitrogen®, 
USA 
EDTA 2-[2-(Bis (carboxymethyl) amino) 
ethyl-(carboxymethyl) amino]acetic 
acid 
C10H16N2O8 292.25 Carl Roth® 
GmbH, 
Germany 
Ethanol Ethanol CH3CH2OH 46.06844 Carl Roth® 
GmbH, 
Germany 
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Ethidium 
bromide 
3,8-Diamino-5-ethyl-6-
phenylphenanthridinium bromide 
C21H20BrN3 394.294 Invitrogen®, 
USA 
Ficoll    Carl Roth® 
GmbH, 
Germany 
Glycerol 
 
Propane-1,2,3-triol C3H5(OH)3 92.09382 Carl Roth® 
GmbH, 
Germany 
Isopropanol Propan-2-ol C3H8O 60.10 Carl Roth® 
GmbH, 
Germany 
Leupeptin  
 
Ac-Leu-Leu-Arg-H; N-acetyl-L-leucyl-
L-leucyl-D,L-argininaldehyde 
Ac - Leu - Leu - 
Arg - CHO 
426.6 Sigma-
Aldrich®, 
USA 
Magnesium 
acetate 
Magnes (CH3COO)2Mg 214.4 Carl Roth® 
GmbH, 
Germany 
Magnesium 
chloride 
Magnesium chloride MgCl2 95.211 Carl Roth® 
GmbH, 
Germany 
Magnesium 
sulphate 
Magnesium sulphate MgSO4 120.415 Carl Roth® 
GmbH, 
Germany 
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Pefabloc  
 
 
4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride 
C8H10FNO2S 203.235 Sigma-
Aldrich®, 
USA 
PEG poly(oxyethylene) C2n+2H4n+6On+2 44n+62 Sigma-
Aldrich®, 
USA 
Pepstatin 3-hydroxy-4-[2-[3-hydroxy-6-methyl-4-
[3-methyl-2-[3-methyl-2-(3-
methylbutanoylamino)butanoyl]amino-
butanoyl]amino-heptanoyl]- 
aminopropanoylamino]-6-methyl-
heptanoic acid 
C34H63N5O9 685.892 Sigma-
Aldrich®, 
USA 
Potassium 
acetate 
 
Potassium acetate CH3COOK 98.15 Carl Roth® 
GmbH, 
Germany 
SDS Sodium dodecyl sulfate NaC12H25SO4 288.38 Carl Roth® 
GmbH, 
Germany 
Sodium chloride Sodium chloride NaCl 58.44277 Carl Roth® 
GmbH, 
Germany 
Sodium 
hydroxide 
Sodium hydroxide NaOH 39.9971 Carl Roth® 
GmbH, 
Germany 
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Sucrose Sucrose C12H22O11 342.29648 Carl Roth® 
GmbH, 
Germany 
Tris 2-Amino-2-hydroxymethyl-propane-
1,3-diol 
C4H11NO3 121.14 Carl Roth® 
GmbH, 
Germany 
Tween 20 Polyoxyethylene (20) sorbitan 
monolaurate 
C58H114O26 1227.54 Carl Roth® 
GmbH, 
Germany 
Xylene cyanol Xylene cyanol C25H27N2O6S2Na 538.61 Carl Roth® 
GmbH, 
Germany 
Zinc chloride Zinc chloride ZnCl2 136.315 Carl Roth® 
GmbH, 
Germany 
β-
mercaptoethanol 
 
2-Hydroxy-1-ethanethiol C2H6OS 78.13 Sigma-
Aldrich®, 
USA 
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2.1.2. Enzymes Table 2.2. List of enzymes 
 
Name of Reagent 
 
 
Purpose 
 
Unit Definition 
 
Company 
Benzonase Removal of nucleic acids 
from protein samples 
Amount of enzyme required to 
completely digest 37 µg of DNA in 
30 minutes under standard assay 
conditions 
Sigma-
Aldrich®, USA 
Calf Intestine Alkaline 
Phosphatase (CIAP) 
Dephosphorylation of 
DNA ends 
1 unit hydrolyzes 1 µmol of p-
nitrophenyl phosphate in 1 minute 
at 37oC 
Invitrogen®, 
USA 
Polynucloetide Kinase 
(PNK) 
Catalyzes the transfer of 
the terminal phosphate of 
ATP to 5' hydroxyl 
termini of polynucleotides 
such as DNA and RNA, 
oligonucleotides and 3' 
mononucleotides 
One unit is the amount of enzyme 
required to incorporate 1 nmol of 
radiolabeled ATP into DNA 
substrate in 30 min at 37°C. 
Usb® (United 
States 
Biochemical), 
USA 
Proteinase K Degradation or removal 
of proteins from samples 
1 unit liberates folin-positive 
amino acids and peptides 
corresponding to 1 µmol of 
tyrosine in 1 minute at 37°C in a 
total reaction volume of 250 µl (1) 
NEB®, USA 
RNase H specifically hydrolyzes 
the phosphodiester 
bonds of RNA which is 
One unit is defined as the amount 
of enzyme that will hydrolyze 1 
nmol of the RNA in [3H]-labeled 
Invitrogen®, 
USA 
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hybridized to DNA poly(rA).poly(dT), to acid-soluble 
ribonucleotides in a total reaction 
volume of 50 µl in 20 minutes at 
37°C in 1X RNase H Reaction 
Buffer with 10 nmol [3H]-labeled 
poly(rA) and 12.5 µg poly(dT). 
RNase I Degradation or removal 
of RNA from samples 
One unit of RNase I degrades 100 
ng of E. coli ribosomal RNA per 
second into acid-soluble 
nucleotides at 37°C in 10 mM 
Tris-HCl (pH 7.5), 100 mM NaCl, 
and 1 mM EDTA 
QIAGEN®, 
Germany 
T4 DNA Ligase Joins the 5' phosphate 
and the 3'-hydroxyl 
groups of DOUBLE 
stranded DNA molecules 
amount of enzyme required to 
give 50% ligation of HindIII 
fragments of λ DNA (5´ DNA 
termini concentration of 0.12 µM, 
300- µg/ml) in a total reaction 
volume of 20 μl in 30 minutes at 
16°C in 1X T4 DNA Ligase 
Reaction Buffer 
NEB®, USA 
T4 DNA Polymerase Converts DNA fragments 
with 3′- and 5′-protruding 
ends to DNA fragments 
with blunt ends 
One unit converts 10 nmoles of 
dNTPs into acid-insoluble material 
in 30 minutes 
at 37oC. 
NEB®, USA 
Thermoscript Reverse 
Transcriptase 
synthesizes DNA from an 
RNA template 
One unit incorporates 1 nmol of 
dTTP into acid-precipitable 
material in 10 min at 37°C using 
Invitrogen®, 
USA 
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poly(A).oligo(dT)25 as template-
primer 
2.1.3. Primers Table 2.3. List of Primers 
Name Sequence Purpose 
VP16TopNot 5'-GATCGCGGCCGCCCTCCTGAAAGATGAAGCTA-
3' 
Amplify VP16 
transactivation 
domain 
VP16BottomXho 5'-GATCTCGAGGCCGCGGATCCCGGACCCGG-3 
CALM2192for 5'-GCAATCTTGGCATCGGAAAT-3 Primer pairs 
that amplify 
the 
CALM/AF10 
break point 
AF10254rev 5'-GCCTGTCGACATCCATGTTT-3 
2.1.4. Plasmids Table 2.4. List of Plasmids 
Name Type 
pEYFP C1 Mammalian expression vector 
pINCO NGFR NGF expressing mammalian expression vector 
pRTS-1 Mammalian expression vector 
pUC19 with SfiI cassette Shuttle vector for subcloning 
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2.1.5. Buffers and Solutions Table 2.5. List of Buffers and Solutions 
 
Name of Buffer/Solution 
 
 
Purpose 
 
Composition 
Blocking Buffer Blocking protein membranes 5 g Milk powder 
0.1% Tween 20 in TBS 
cDNA Synthesis Buffer Reverse transcriptase reaction Buffer 250 mM Tris acetate, pH 8.4  
375 mM potassium acetate 
40 mM magnesium acetate  
20 μg/ml BSA 
CIAP dilution Buffer Dilution buffer for CIAP 25mM Tris.Cl, pH 7.6 
1mM MgCl2  
0.1 mM ZnCl2 
50% Glycerol (v/v) 
Dephosphorylation Buffer Dephosphorylation Buffer 50mM Tris.Cl, pH 8.5         
0.1 mM EDTA 
EB Buffer DNA elution buffer  10 mM Tris·Cl, pH 8.5 
ER  Confidential 
Fetal Calf Serum (FCS) Supplement to culture media GIBCO®, USA 
FT LYSIS Buffer Cell lysis for protein extraction 600 mM KCl 20 mM  
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Tris.Cl, pH 7.8  
20% Glycerol 
Laemmli Buffer Protein sample preparation 4% SDS 
20% glycerol 
10% β-mercaptoethanol 
0.004%  bromphenol blue 
0.125 M Tris.Cl, pH 6.8 
Ligation Buffer Buffer for ligation reaction 132 mM Tris-HCl, pH 7.6 
 20 mM MgCl2, 
2 mM dithiothreitol 
2 mM ATP  
15% Polyethylene glycol 
(PEG 6000) 
Loading dye Dye used for loading DNA and RNA 
samples on agarose gels 
Bromophenol blue (0.25%) 
Xylene xyanol (0.25%) 
Sucrose (40%)  
H2O 
Lysis Buffer Mammalian Genomic DNA extraction 100 mM Tris.Cl pH 8.5  
5 mM EDTA 
0.2% SDS  
200 mM NaCl 
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100 µg Proteinase K/ml 
 
MACS Buffer Magnetic Activated Cell Sorting Buffer 2.5 g BSA/500 ml approx. 
0.5%; 2 ml EDTA 0.5 M 
Non Essential Amino Acids 
(NEAA) 
Supplement to culture media GIBCO®, USA 
OPTIMEM Electroporation medium for mammalian 
cells 
GIBCO®, USA 
P1 Buffer Resuspension buffer for bacterial pellets 50 mM Tris.Cl pH 8.0 
10 mM EDTA 
100 µg/ml Rnase A 
P2 Buffer Lysis Buffer 200 mM NaOH 
1% SDS (w/v) 
P3 Buffer Neutralization Buffer 3.0 M Potassium Acetate pH 
5.5 
PBS Phosphate Buffered Saline GIBCO®, USA 
PCR Buffer Traditional PCR Buffer 500 mM KCl  
100 mM Tris.Cl ,pH 9.0, 
1.0% Triton X 100) 
Protein inhibitor cocktail  Solution for freeze thaw protein exptraction 
procedure 
0.4 mg/ml Pefabloc  
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10 µg/ml Leupeptin  
10 µg/ml Pepstatin  
5 µg/ml Aprotinin 
 
Pyruvic acid Supplement to culture media GIBCO®, USA 
QBT Buffer Equilibration Buffer 750 mM NaCl 
50 mM MOPS, pH 7.0 
15% Isopropanol (v/v) 
0.15% Triton® X-100 (v/v) 
QC Buffer Wash Buffer 1.0 M NaCl 
50 mM MOPS, pH 7.0 
15% Isopropanol (v/v) 
QG Buffer Gel solubilization buffer Confidential 
QN Buffer Elution Buffer 1.6 M NaCl 
50 mM MOPS, pH 7.0 
15% Isopropanol (v/v) 
T4 DNA Polymerase Buffer T4 DNA Polymerase Buffer 330 mM Tris-acetate, pH 7.8  
660 mM potassium acetate 
100 mM magnesium acetate  
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5 mM DTT 
T4 PNK Buffer T4 PNK Buffer 0.5 M Tris.Cl, pH 7.6 
100 mM MgCl2 
100 mM β-mercaptoethanol 
 
TAE Buffer Agarose electrophoresis Buffer Tris base 
Glacial acetic acid 
EDTA, pH 8.0 
TBE Buffer Agarose electrophoresis Buffer Tris base 
Boric acid 
EDTA, pH 8.0 
TBS Transfer Buffer for SDS-PAGE transfer 
setup 
192mM Glycine 
25mM Tris 
20%Methanol 
TE Buffer Resuspension of air dried DNA 10 mM Tris.Cl  pH 7.5 
0.1 mM EDTA  
TRIZOL® RNA extraction solution Guanidinium thiocyanate-
phenol-chloroform 
Trypan Blue Counting cells GIBCO®, Germany 
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2.1.6. Media 
2.1.6.1. Bacterial culture 
Table 2.6. Bacterial culture medium and agar 
 
Name of Media 
 
 
Purpose 
 
Company 
Liquid Broth (LB) Agar Solid medium for bacteria culture Carl Roth® GmbH, Germany 
Liquid Broth (LB) Medium Liquid medium for bacteria culture Carl Roth® GmbH, Germany 
 
2.1.6.2. Mammalian cell culture 
Table 2.7. Mammalian cell culture medium 
 
Name of Media 
 
 
Purpose 
 
Company 
DMEM Culture media for adherent 
cells 
GIBCO®, USA 
RPMI 640 Culture media for suspension 
cells 
GIBCO®, USA 
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2.1.7. Antibodies 
Table 2.8. List of Antibodies 
 
Name 
 
 
Description 
 
Company 
Anti AF10 Recognizes the AF10 protein HelmholtzZentrum Muenchen, 
Germany 
Anti CALM Recognizes the Clathrin 
Assembly Lymphoid Myeloid 
(CALM) protein 
Santa Cruz Biotechnology® Inc., 
USA 
Anti FLAG Detects the FLAG tag Sigma-Aldrich®, USA 
Anti GFP Recognizes the Green 
Fluorescent  Protein (GFP) 
Roche®, Switzerland 
Anti NGF Recognizes the cell membrane 
protein NGF 
Miltenyi®, Germany 
2.1.8. Cells 
2.1.8.1. Bacterial Cells Table 2.9. List of chemo/electro-competent bacteria used for transformation 
 
Name 
 
 
Description 
 
Company 
DH5α Chemically competent cells for 
transformation purposes 
Invitrogen®, Germany 
INV 110 Electrocompetent/chemically 
competent bacterial cells that are 
dam- 
Invitrogen®, Germany 
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XL1Blue Electrocompentent bacteria cells  Invitrogen®, Germany 
2.1.8.1. Mammalian Cells Table 2.10. List of Mammalian cell lines used 
 
Name 
 
 
Description 
 
Source 
293T Human Embryonic Kidney cells HelmholtzZentrum Muenchen, 
Germany 
DG75 
 
HelmholtzZentrum Muenchen, 
Germany 
H1299 human lung cancer cell line HelmholtzZentrum Muenchen, 
Germany 
 
2.1.9. Computer Operating System and Application Software Table 2.11. List of software and applications       
 
Software  
 
Purpose  
   
 
Company/Source 
Adobe Photoshop CS2 Image analysis application Adobe® Inc., USA 
dChip Microarray analysis tool Harvard (Li Wong), USA 
Endnote X1 Reference manager application Thompson® Company, USA 
Gene Pattern 3.1.1 Microarray analysis suite Broad MIT, USA 
Image J 1.410 Image analysis software National Institute of Health, USA 
Linux Fedora Core 8 and 9 Core Operating System Open Source/Fedora Project 
Macromedia Freehand MX Drawing and image processing 
application 
Adobe® Inc., USA 
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Microsoft Office 2007 Office applications Microsoft® Company, USA 
R Statistical Package 2.3 – 2.8 Freeware statistical package CRAN, International 
SDS 2.1 Sequence Detection System for 
Taqman Real Time PCR 
Applied Biosystems®, USA 
STATISTICA 7 Multipurpose statistical software Statsoft® Inc., USA 
Vector NTI Suite 10 Molecular Biology and related 
fields application Suite 
Invitrogen® Company, USA 
Windows Vista Core Operating System Microsoft® Company, USA 
Windows Xp Core Operating System Microsoft® Company, USA 
2.1.10. Equipments and Utensils 
Table 2.12. List of equipments and utensils 
 
Name of Item 
 
Purpose 
 
 
Company 
7900HT system Real Time PCR 
System 
Station for running Taqman® 
Real Time PCR reactions 
Applied Biosystems®, USA 
Bacteria culture dish Petri-dish for culturing bacteria Corning Life Sciences, USA 
Mammalian cell culture dish Plates for growing mammalian 
cells 
Corning Life Sciences, USA 
Mammalian cell culture flask Flask for culturing mammalian 
cells 
Sarstedt®, Germany 
Conical Flask Multipurpose plasticware for 
routine lab activities 
Falcon®, Germany 
EasyjecT Prima Bacteria electroporation device EquiBio® Co., UK 
Graduated Cylinder Measuring volumes VIT-LAB® GmbH, Germany 
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High speed Centrifuge with 
thermoregulator 
For cooled centrifugation 
purposes  
(max. centrifugation  21160 rcf) 
Eppendorf®, USA 
High volume Centrifuge with cooling 
system 
For centrifugation of large 
volumes (max speed 4,500 
rpm) 
Sigma®, Germany 
Incubator Shaker For incubating samples at 
specific temperature and 
rotations, mainly bacterial 
cultures 
Innova®, USA 
Micro Fluidic Card Sample Block 
(Also referred to as the thermal 
cycler module or thermal block) 
Metal heating block required for 
running low density array cards 
Applied Biosystems®, USA 
 
Micro Fluidic Card Sealer To seal LDA cards Applied Biosystems®, USA 
 
Microfuge Tubes (1.5 ml) Multipurpose plastic tubes for 
routine lab activities 
Eppendorf®, Germany 
Pipette tips Plastic tips fitting to pipettes Carl Roth® GmbH, Germany 
Micropipettes Tool for measuring, adding, 
removing, and mixing small 
volumes of solutions 
Gilson® Co., USA 
QIAfilter Cartridge with cap and 
Plunger 
Filtration column during 
maxiprep 
(filters debries and proteins) 
QIAGEN®, Germany 
QIAGEN-tip 500 Column for filtering and eluting 
DNA 
QIAGEN®, Germany 
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QIAquick column Column for filtering solubilized 
agarose gel from DNA 
QIAGEN®, Germany 
Sorvall/Heraeus Custom Buckets 
and Adaptors (4 pcs.) 
Centrifugation buckets for LDA 
cards 
Thermo Fisher® Scientific, USA 
Table-top Centrifuge Routine centrifugation needs 
(max. speed 14,000 rpm) 
Eppendorf®, Germany 
2.2. Methods 
2.2.1. Extraction 
2.2.1.1. Nucleic Acids Extraction 2.2.1.1.1. DNA Extraction 
2.2.1.1.1.1. Mammalian Genomic DNA extraction 
 
This protocol was adopted from (Laird, 1991). Cells were grown in a 6 well plate 
(approximately 4 x 106 cells) were used as a starting material. The culture media was 
removed and cells were washed twice with PBS by centrifugation (1100 rpm at 4oC). 
Lysis buffer, which has been adjusted to allow enzymatic manipulation of the DNA 
without prior organic solvent extractions, was added to the washed cells. The procedure 
involved just three manipulations: 
1. Addition of lysis buffer to the tissue or cells 
2. Addition of isopropanol 
3. Transfer of precipitate to TE 
1. Lysis: The lysis buffer (0.5 ml) was added to the cells. Digestion was complete within 
4 hours at 37°C with agitation. 
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2. Isopropanol precipitation: One volume of isopropanol was added to the lysate and 
the samples were mixed or swirled until precipitation was complete (viscosity 
completely gone). 
3. Recovery of precipitate: The DNA was recovered by lifting the aggregated precipitate 
from the solution using a disposable yellow tip. Excess liquid was dabbed off and the 
DNA was dispersed in a pre-labeled Eppendorf tube containing, depending on the size 
of the precipitate, 20 to 500 µl of TE Buffer. Complete dissolution of the DNA may 
require several hours of agitation at 37°C. It is important that the DNA is completely 
dissolved to ensure the reproducible removal of aliquots for analysis. 
2.2.1.1.1.2. Plasmid DNA Extraction 
Miniprep 
Approximately 1.5 ml of a bacterial overnight culture was centrifuged at 11,000 rpm for 
approximately 1 minute. The supernatant was decanted and the pellet was resuspended 
with 300 µl Buffer P1. 300 µl P2 was immediately added and was the mix was left at 
room temperature for 5 minutes. Following the 5 minute incubation, 300µl P3 was added 
and samples were centrifuged at 14,000 rpm for 10 minutes. 900 µl of the supernatant 
was taken and transferred to a fresh tube. Plasmid DNA was precipitated by adding 0.7 of 
volume isopropanol. Tubes were kept at -20°C for 10 minutes and were later centrifuged 
for 30 minutes at 4°C. The supernatant was discarded and the pellet was washed with 
70% Ethanol by centrifuging at 14,000 rpm for 15 minutes. The supernatant was 
discarded and the pellet was dried at room temperature for 10 minutes. The pellet was 
resuspended with 20 µl of 1x TE buffer and kept at -20oC for future use. 
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Maxiprep 
The whole protocol has been adopted from QIAGEN EndoFree® Plasmid Purification 
Handbook (http://www1.qiagen.com/HB/CompactPrep_EN). A single bacterial colony 
was picked from a freshly streaked selective plate and a starter culture of 2–5 ml LB 
medium containing the appropriate selective antibiotic was inoculated. The starter culture 
was incubated overnight at 37°C with vigorous shaking (approx. 300 rpm). A tube or 
flask was used with a volume of at least 4 times the volume of the culture. The starter 
culture was diluted 1/500 to 1/1000 into selective LB medium. For high-copy plasmids, 
100 ml medium was inoculated with 100–200 μl of starter culture. For low-copy 
plasmids, 250 ml medium was inoculated with 250–500 μl of starter culture. The culture 
was grown at 37°C for 12–16 h with vigorous shaking (approx. 300 rpm). A flask with a 
volume of at least 4 times the volume of the culture was used. The culture usually reaches 
a density of approximately 3–4 x 109 cells/ml, which typically corresponds to a pellet wet 
weight of approximately 3 g/liter medium. Bacterial cells were harvested by 
centrifugation at 6000 x g for 15 min at 4°C. If there was a need to stop the procedure, 
cells were frozen at -20oC. The bacterial pellet was resuspended in 10 ml Buffer P1. For 
efficient lysis it is important to use a vessel that is large enough to allow complete mixing 
of the lysis buffers. The pellet was resuspended completely by vortexing or pipetting up 
and down until no cell clumps remained. Following Resuspension, 10 ml Buffer P2 was 
added and mixed thoroughly by vigorously inverting the sealed tube 4–6 times, and 
incubated at room temperature (15–25°C) for 5 min. During the incubation the QIAfilter 
Cartridge was prepared. 10 ml pre-chilled Buffer P3 was added to the lysate and mixed 
immediately and thoroughly by vigorously inverting 4–6 times. Precipitation is enhanced 
by using chilled Buffer P3. The lysate was poured into the barrel of the QIAfilter 
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Cartridge and incubated at room temperature (15–25°C) for 10 min. The cap was 
removed from the QIAfilter Cartridge outlet nozzle. The plunger was gently inserted into 
the QIAfilter Maxi Cartridge and the cell lysate was filtered into a 50 ml tube. 
Approximately 25 ml of the lysate is generally recovered after filtration. 2.5 ml Buffer 
ER was added to the filtered lysate and was mixed by inverting the tube approximately 
10 times and incubating on ice for 30 min. QIAGEN-tip 500 was equilibrated by 
applying 10 ml Buffer QBT and the column was allowed to empty by gravity flow. The 
filtered lysate was applied to the QIAGEN-tip and allowed to enter the resin by gravity 
flow. The QIAGEN-tip was washed with 2 x 30 ml Buffer QC. Buffer QC was allowed to 
move through the QIAGEN-tip by gravity flow. DNA was eluted with 15 ml Buffer QN. 
DNA was precipitated by adding 10.5 ml (0.7 volumes) room-temperature isopropanol to 
the eluted DNA. The mix was centrifuged immediately at ≥15,000 x g for 30 min at 4°C. 
The supernatant was carefully decanted. DNA pellet was washed with 5 ml of endotoxin-
free room-temperature 70% ethanol and centrifuged at ≥15,000 x g for 10 minutes. 
Again, the supernatant was carefully decanted without disturbing the pellet. The pellet 
was Air-dried for 5–10 min, and re-dissolved in a suitable volume of endotoxin-free 
Buffer TE. 
2.2.1.1.1.3. Organic precipitation of DNA 
This method is useful for precipitation of DNA from enzymatic reactions. 0.6 volume of 
isopropanol is added to the sample. After mixing the sample, 2 volumes of 95% cold 
ethanol were added and sample was placed at -80oC for 30 minutes. Following the 
incubation, the sample was centrifuged at 12,000 rpm at 4oC for 25 minutes. The 
supernatant was decanted and the pellet was drained by inverting the eppendorf tube. 2 
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volumes of 80% room temperature ethanol were added to the sample and incubated at 
room temperature for 10 minutes. The sample was centrifuged for at 12,000 rpm at 4oC 
for 7 minutes. The supernatant was decanted and pellet air dried for 5 – 10 minutes at 
room temperature and resuspended in suitable volume of TE buffer or water. 
2.2.1.1.2. RNA Extraction 
Cells Grown in Suspension were pelleted by centrifugation. Cells were lysed in 
TRIZOL® Reagent by repetitive pipetting. 1 ml of TRIZOL® reagent per 5-10 × 106 of 
cells was used. Washing cells before addition of TRIZOL® Reagent was avoided as this 
increases the possibility of mRNA degradation. Insoluble material was removed from the 
homogenate by centrifugation at 12,000 × g for 10 minutes at 2 to 8°C. The resulting 
pellet contains extracellular membranes, polysaccharides, and high molecular weight 
DNA, while the supernatant contains RNA. The cleared homogenate solution was 
transferred to a fresh tube. The homogenized samples were incubated for 5 minutes at 15 
to 30°C to permit the complete dissociation of nucleoprotein complexes. 0.2 ml 
chloroform per 1 ml of TRIZOL® reagent was added. Tubes were shaken vigorously by 
hand for 15 seconds and incubated at 15 to 30°C for 2 to 3 minutes. The samples were 
centrifuged at no more than 12,000 × g for 15 minutes at 2 to 8°C. Following 
centrifugation, the mixture separates into a lower red, phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remains exclusively in the aqueous 
phase. The volume of the aqueous phase is about 60% of the volume of TRIZOL® 
reagent used for homogenization. Transfer the aqueous phase to a fresh tube, and save the 
organic phase if isolation of DNA or protein is desired. RNA was precipitated from the 
aqueous phase by mixing with isopropanol. 0.5 ml of isopropanol per 1 ml of TRIZOL® 
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Reagent used for the initial homogenization was used. Samples were incubated at 15 to 
30°C for 10 minutes and centrifuged at 12,000 × g for 10 minutes at 2 to 8°C. The RNA 
precipitate forms a gel-like pellet on the side and bottom of the tube. The supernatant was 
removed. The RNA pellet was washed once with 75% ethanol, adding at least 1 ml of 
75% ethanol per 1 ml of TRIZOL® Reagent used for the initial homogenization. The 
sample was mixed by vortexing and centrifuged at 7,500 × g for 5 minutes at 2 to 8°C. 
The RNA pellet was air-dried for 5 minutes and was dissolved in RNase-free water by 
passing the solution a few times through a pipette tip, and incubating for 10 minutes at 55 
to 60°C.  
2.2.1.1.3. Protein Extraction 
2.2.1.1.3.1. Freeze thaw method 
The culture medium was removed from the cells, and the cells werer washed in ice-cold 
PBS. The sample was transferred to 1.5 ml microfuge tube. Cells were pelleted at top 
speed in a microfuge (45s in cold-room). The pellet was resuspended in FT LYSIS Buffer 
(25-40 µl per confluent 6 cm dish, 50-80 µl per confluent 10 cm dish). The tubes were 
dropped into liquid nitrogen for shock-freezeing. The samples were taken out of the 
liquid nitrogen (once they are frozen) and thawed on ice and were vortexed briefly. The 
freeze-thaw cycle was repeated two more times. Finally, 250 U of Benzonase was added 
to the samples to digest DNA and incubated at room temperature for 10 minutes. Protein 
concentration was measured by Bradford method. Equal volume of 2xLaemmli Buffer 
was added prior to analysis by SDSPAGE and heated at 95°C for 10 minutes. Samples 
were loaded on the gel immediately (Note that these samples must be loaded while still 
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warm, because the salt in the FT Buffer will cause the SDS in the Laemmli  buffer to 
precipitate when cold). 
2.2.1.1.3.2. RIPA lysis method 
Cells were spun at 1000 rpm for 10 minutes at 4oC. The supernatant was removed and 
pellet was resuspended with cold PBS (approximately 1 ml per 10 cm dish). Cells were 
further centrifuged using the same settings and washed once more with cold PBS. The 
supernatant was removed and pellet was resuspended with 80 µl RIPA Buffer with 
protein inhibitors. The samples were gently mixed in a radial rotor at 15 rpm for 30 
minutes at 4oC. Following the incubation, the samples were centrifuged for 10 minutes at 
14,000 rpm at 4oC. Supernatant was collected in new tubes and the protein amount was 
quantified using the Bradford method. 
2.2.2. DNA digestions and modifications 
2.2.2.1. Restriction Endonuclease digestion 
DNA restriction endonuclease digestion is usually carried out with a 2-fold to 10-fold 
excess of restriction enzyme in the total volume of 20 µl using 0.2-1.5 µg of DNA. A 
typical restriction enzyme digestion protocol is presented below. The components were 
added in the following order for a 20 µl reaction: 
Table 2.13. Typical reaction mix setup for restriction digestion. 
Component Volume 
Water, nuclease-free 16 µl 
10X recommended buffer for restriction enzyme 2 µl 
Substrate DNA 1 µl (~1 µg) 
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Restriction enzyme  0.5-1 µl (5-10 u) 
Samples were mixed gently and spun down briefly.  Incubation was carried out at the 
optimum temperature for 1-16 hours. The digestion reaction may be scaled up or down. 
2.2.2.2. Dephosphorylation 
The following protocol was adapted from Invitrogen with some modifications. It was 
used to dephosphorylate vector backbones digested with one restriction enzyme that were 
subsequently used in cloning experiments. 
The mass of DNA required for 1 pmol 5′ end was determined by applying the following 
relations: 
   
Once the required amount of DNA was determined (amount of DNA having the required 
1pmol of DNA ends), the following components were added to a microfuge tube: 
 4 µl of 10X dephosphorylation Buffer 
 1 pmol of DNA ends 
 Distilled water to 39 µl 
The calf intestinal phosphatase (CIAP) was diluted in Dilution Buffer such that 1 µl 
contains the amount of enzyme required for the appropriate 5′ end (i.e. 1 unit for 5′ -
recessed and blunt ends and 0.01 units for a 5′ overhang). For 5′ -recessed and blunt-
ended DNA, samples were incubated at 50°C for 60 minutes and samples with 5′ 
pmol ends = pmol DNA  [(number of cuts  2) + 2]
1 g of 1000 bp DNA = 3.04 pmol endsµ
× ×
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overhang were incubated at 37°C for 30 minutes. Samples were later run on Agarose gel 
and extracted or precipitated by organic extraction.  
Occasionally, a simplified protocol was also employed. This protocol allows for the 
dephosphorylation of DNA directly in restriction endonuclease buffer in the presence of 
the restriction endonuclease by adding 1 unit of CIAP and incubating samples at 50°C for 
5 minutes blunt-ended DNA and 37°C for 5 minutes for DNA with 5′ overhang. 
2.2.2.3. Phosphorylation 
This protocol is written for 10 pmol of oligonucleotide. It can be scaled up or down 
accordingly. The oligonucleotide can be in any volume up to 25 μl of water or buffer, pH 
7.6. 
The reaction mixture was as follows: 
Table 2.14. Phosphorylation reaction mix 
Component Volume 
Oligonucleotide (10 pmol)  __ μl 
ATP  __ μl 
T4 Polynucleotide Kinase (PNK) buffer (10X)  5 μl 
T4 Polynucleotide Kinase (PNK) (diluted)  2-5 units 
Water  __ μl 
Total  50 μl 
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The contents were mixed well and centrifuged briefly. Incubate was carried out at 37°C 
for 30 minutes and reaction was terminated by heating at 65°C for 10 minutes or adding 
EDTA to 5mM.  
2.2.2.4. Blunting 
This protocol allows the conversion of DNA fragments with 3′- and 5′-protruding ends to 
DNA fragments with blunt ends. Conversion of the two types of protruding ends can be 
accomplished simultaneously by the 3'->5' exonuclease and 5'->3' polymerase activities 
of the T4 DNA Polymerase.  
The reaction mix was: 
Table 2.15. Reaction mix for blunting procedure 
Component  Volume 
DNA fragment (with protruding ends)  > 0.1 pmol 
10X Buffer 1 µl 
Distilled sterile water up to 9 µl 
Total Volume 9 µl 
Samples were incubated at 70°C for 5 minutes. 1 µl of T4 DNA Polymerase was added 
and mixed gently by pipetting.  Incubation was carried out at 37°C for 5 minutes. For 
DNA samples with low G+C content, incubation was done 25°C instead of 37°C. DNA 
Dilution Buffer was added to bring the DNA concentration to 1 µg/50 µl and mixed 
thoroughly. Samples were later placed on ice to ensure deactivation of T4 DNA 
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Polymerase. If the solution was to be stored, DNA extraction was done immediately by 
organic extraction.  
2.2.2.5. Ligation 
Ligation experiments are usually carried out in 3:1 proportion of insert to vector 
backbone ratio. The required amount of insert is calculated by using the following 
formula: 
      V I 3I
V 1
a s
a
s
×
= ×  
Where Ia is the concentration of insert required, Va is the amount of vector to be used, 
and Is and Vs are insert size and vector size in base pairs, respectively.  Reaction mix was: 
Table 2.16. Ligation reaction setup 
Component Main reaction Control 1 (no 
insert) 
Control 2 (no 
vector) 
Vector backbone __ µl __ µl x 
Insert __ µl x __ µl 
T4 DNA Ligase   1 µl   1 µl   1 µl 
Ligation Buffer   2 µl   2 µl   2 µl 
Nuclease Free Water to 20 µl to 20 µl to 20 µl 
For blunt-end ligation PEG (up to 15%) was added to increase the efficiency. 
Incubation was carried out according to the guidelines below: 
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o Sticky end ligation reactions at room temperature for 1-2 hours (or at 4oC 
in an ice-water mix that slowly thaws to room temperature overnight).  
o Blunt-end ligation reactions at 4oC in an ice-water mix that slowly thaws 
to room temperature overnight.  
2.2.3. Transformation 
2.2.3. 1.  Preparation of electro-competent bacteria Cells 
500 ml LB Medium was inoculated with a starter (a single bacterial colony that had been 
cultured in 3 ml LB medium overnight) culture and was mixed well. OD600 measurement 
was carried out every 45 min. Once the OD600 reading was in the range 0.40-0.60, the 
flask was taken out of the shaker and put in an ice-water bath for 15 min. The culture was 
then distributed in 8 (50 ml each) conical bottom Falcon tubes and cells were pelleted at 
4500 x g for 5 min at 4°C. The supernatant was discarded and cells were resuspended in 
40 ml ice cold water by pooling pellet from all tubes into one tube and subsequently 
centrifuged at 4500 x g for 5 min at 4 °C. Supernatant was again discarded and cells were 
resuspended in 40 ml ice cold water. Further centrifugation was carried out at 4500 x g 
for 5 min at 4 °C. After discarding the supernatant, cells were washed in 40 ml 10% 
glycerol (prepared my mixing with ice cold water) and centrifuged at 4500 x g for 5 min 
at 4 °C. Supernatant was discarded and the pellet was resuspended again in 40 ml 10% 
glycerol and centrifuged at 4500 x g for 5 min at 4 °C. Finally, 50 µl aliquots were 
prepared in 1.5 ml eppendorf tubes. The aliquots were immediately frozen in liquid 
nitrogen and later stored at -80 °C. 
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2.2.4. Electroporation 
Electroporation is a procedure by which foreign DNA is introduced into cells by 
electrical pulse. The concise protocol is as follows. Frozen electro-competent bacterial 
cells were thawed on ice and mixed with the required amount of DNA, usually higher 
than 20 ng, and incubated further on ice for 1 minute. The mix was pipetted into 
electroporation cuvette and put on EasyjecT Prima electroporation device. The sample 
was pulsed with high voltage (1800-2500 volts) which lasts for few seconds. After a 
signal that the pulse was successful, sample was resuspended in 1 ml antibiotic free room 
temperature LB medium and incubated for approximately 45 minutes at 37oC in an 
incubator with a shaker set to 220 rpm. Sample was later plated on an LB agar plate with 
the appropriate antibiotic selection. 
2.2.5. Electrophoresis 
2.2.5.1. DNA electrophoresis 
DNA electrophoresis is a technique by which DNA fragments are separated by 
application of electric current by letting the fragments move through a matrix. The 
separation, as DNA is negatively charged, is based on size whereby larger fragments 
move slower and are more cathodal while smaller fragments move faster and are anodal. 
There are two buffer systems employed for standard DNA electrophoresis procedures: 
Tris Acetate EDTA (TAE) and Tris Borate EDTA (TBE). Tris-borate buffer (TBE) was 
advantageous for obtaining a higher resolution of smaller DNA fragments on agarose 
gels, when compared to the conventional tris-acetate buffer (TAE)(Yutaka MIURA, 
1999). Critical DNA sizes and gel concentrations for a clear separation were about 2-kb 
for the 0.8% agarose and 300-bp for the 2.0% agarose. DNA fragments larger than the 
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critical size (>2-kb on 0.8% agarose gel) migrate faster in TAE, and the smaller 
fragments (<300-bp on 2% agarose gel) migrate faster in TBE showing the better 
resolution in a mini chamber system. Routine preparations were 0.8-1% agarose, which 
were prepared by mixing 400 – 500 mg agarose with 50 ml 0.5x or 1x TAE/TBE. 3 µl 
from 10 mg/ml Ethidium bromide was added after the temperature of the gel was below 
55oC. The gel was left to solidify at room temperature for 15 to 20 minutes. Samples to 
be loaded were mixed with Loading dye (1x final concentration) and loaded on the gel 
after submerging the gel in the same buffer used for preparing it. Runs usually took 45 to 
90 minutes at 90 Volts, depending on the size of DNA size to be analyzed. 
2.2.5.2. RNA electrophoresis 
Gel preparation for whole RNA electrophoresis was 1.2% agarose in 0.5xTBE. Samples 
were mixed with loading dye (1x final concentration) and loaded on the gel. 
Electrophoresis was conducted at 90 Volts for 60 minutes. 
2.2.5. Gel Purification 
This protocol, adapted from QIAGEN® QIAquick Gel Extraction Kit Protocol, is 
designed to extract and purify DNA from standard or low-melt agarose gels in TAE or 
TBE buffer. Up to 400 mg agarose can be processed per spin column. This kit can also be 
used for DNA cleanup from enzymatic reactions. 
DNA fragment was excised from the agarose gel with a clean, sharp scalpel. Gel slice 
was weighed in a colorless tube. 3 volumes of Buffer QG were added to 1 volume of gel 
(100 mg ~ 100 μl). The maximum amount of gel slice per QIAquick column is 400 mg. 
Sample was incubated at 50°C for 10 min. To help dissolve gel, sample was mixed by 
vortexing the tube every 2–3 min during the incubation. 1 gel volume of isopropanol was 
Materials and Methods 
48 
 
added to the sample and mixed thoroughly. To bind DNA, the sample was applied to the 
QIAquick column, and centrifuged for 1 min at 13,000 rpm. Flow-through was discarded 
and QIAquick column was placed back in the same collection tube. 0.75 ml of Buffer PE 
was added to QIAquick column and centrifuged for 1 min at 13,000 rpm. The column 
was left to stand 2–5 min after addition of Buffer PE before centrifuging. Flow-through 
was again discarded and the QIAquick column was centrifuged for an additional 1 min at 
17,900 x g (13,000 rpm). QIAquick column was placed into a clean 1.5 ml 
microcentrifuge tube. To elute DNA, 30 μl of Buffer EB (10 mM Tris·Cl, pH 8.5) or 
water (pH 7.0–8.5) was added to the center of the QIAquick column membrane and was 
left to stand for 1 minute before centrifuging it for 1 minute. 
2.2.6. Cell Culture 
The following protocols have been adapted, with some modifications, from Sigma 
Aldrich® cell culture handbook and SAFC® biosciences general cell culture techniques 
manual. 
2.2.6.1. Serum Preparation 
Animal serum is an excellent natural source of nutrients for cells in culture because it 
contains proteins, lipids, salts, vitamins, minerals, amino acids and other components 
necessary for growth. When stored and handled correctly, the performance characteristics 
of serum can be maintained for many years. Serum was stored frozen (-10 to -40 °C) and 
protected from light.  
2.2.6.1.2. Thawing Procedure  
The serum bottle was taken out from the freezer and allowed to acclimate to room 
temperature for approximately 10 minutes. The container was placed in a 30 - 37°C water 
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bath or incubator and swirled every 10 - 15 minutes until the serum was completely 
thawed. 
2.2.6.1.3. Heat Inactivating Serum  
Heat inactivation of serum, which degrades complement proteins by raising the 
temperature of the serum to 56 °C for 30 minutes, is a required step before the serum 
could be used. To achieve this, thawed serum bottles were put in a water bath and were 
periodically agitated. The serum bottles were removed after 30 minutes at 56 °C. The 
serum was aliquoted in 50 ml falcon tubes and was allowed to cool before using it on 
cells. Unused portions were refrozen for later use. 
2.2.6.2. Media preparation 
RPMI640 was used for culturing suspension cells, DG75. The medium was supplemented 
with 10% Calf Feotal Serum (CFS), 1% NEAA and 1% Pyruvic acid. Complete medium 
was stored at 4oC until further use. 
2.2.6.3. Growing cells 
The following protocol has been adapted, with some modifications, from Sigma Aldrich® 
cell culture handbook.  
DG-75 Cells are round to polygonal, single or clustered cells in suspension (pre-warmed 
90% RPMI 1640 + 10% FBS). They are maintained at 0.1-0.5 x 106 cells/ml and 
subcultured 1:5 to 1:10 every 24-48 hours. The doubling time is 40-50 hours and 
saturation density is 0.75-1.0 x 106 cells/ml (DSMZ, 2008).  
Suspension cells Flasks (T25, T75 and T175) were used to culture the cells. Cultures 
were viewed using an inverted phase contrast microscope. Cells growing in exponential 
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growth phase are bright, round and refractive. Occasionally, cells were very sticky and 
required a gentle knock to the flask to detach them. Overgrowth of cells was monitored 
by checking the change in pH of the medium, indicated by change in color of the phenol 
in the medium from red to yellow. For sub-culturing, the cells were allowed to settle to 
the bottom of the flask for 10 – 20 minutes. Once they have settled, the supernatant was 
removed by leaving a thin layer of cells at the bottom of the flask. Desired number of 
cells (after calculating cells/ml) was re-seeded into freshly prepared flasks without 
centrifugation just by diluting the cells. This was repeated every 2-3 days. 
2.2.6.4. Counting cells 
 
Trypan blue is the stain most commonly used to distinguish viable from nonviable cells. 
Viable cells exclude the dye, while nonviable cells absorb the dye and appear blue when 
viewed with a microscope. Cells should be in suspension as single cells in medium or a 
buffered saline before counting. Trypan blue has a higher affinity for serum protein than 
for cellular protein, so suspending cells in medium containing serum generates a dark 
background.  
Trypan blue was first diluted with Phosphate Buffered Saline (PBS) to a working 
concentration of 0.02% - 0.04%. Cells were prepared in duplicate for counting in 1:100 
dilutions in trypan blue solution. After being stained with trypan blue, the cells were 
counted within three minutes to avoid staining of viable cells as they will begin to take up 
the dye. A small amount of the stained cell suspension was placed onto the slot of a clean 
hemacytometer with coverslip. The cell suspension passed under the coverslip by 
capillary action. The opposite chamber was filled with the second diluted sample. The 
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hemacytometer was placed on the stage of an inverted microscope and the focus and 
power was adjusted until a single counting square fills the field. If the counts differed by 
more than 20%, a third sample was prepared to verify the count. The viable cell number 
was calculated using the formula:  
4Number of viable cells CountedViable Cell Number/ml = 10 Dilution Factor
Number of Squares Counted
× ×
 
2.2.6.5. Freezing cells 
Cryopreservation is an efficient method by which cells are stored in liquid nitrogen (-
196oC) without significantly losing their viability. The following procedure describes a 
quick method by which cells can be frozen. 
Freezing medium was prepared by mixing 90% fetal calf serum and 10% dimethyl 
sulfoxide (DMSO). Cells were harvested in mid-logarithmic growth using standard 
procedures. The cell count was obtained by pelleting the cells by centrifugation. Cells 
were put in the freezing medium at a density of approximately 5 × 106 cells/ml. The cells 
were aliquoted into sterile vials or ampules. Cells were frozen in a rate-controlled freezer 
unit overnight. Cells were frozen in the vapor phase of liquid nitrogen.  
2.2.6.6. Thawing cells 
A vial of cells was removed from the vapor phase of liquid nitrogen. The vial contents 
were allowed to thaw by continuously swirling the vial in a 37°C water bath until only a 
small ice pellet remained. The vial was sprayed down with a 70% alcohol solution and 
was allowed to evaporate. 10 - 20 ml cold PBS was added to the cells and resuspended. 
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Cells were centrifuged at 1000 rpm for 10 minutes at 4°C. Supernatant was discarded and 
10 ml fresh medium was added to the cells. Cells were cultured in an incubator at 37°C 
with 5% CO2. 
2.2.6.7. Kill Curve Analysis and stably transfected cells 
Cells are often transfected with expression vectors containing antibiotic (e.g. puromycin 
or hygromycin) resistance markers that play key role in the enrichment of transfected 
cells by selectively killing non transfected ones and thereby contributing to the 
establishment of stably transfected cell lines. To meet such an end, one needs to 
determine the exact concentration of the selection agent required to achieve a 
predetermined level of selection. This is done by initially determining the LDx (Latent 
Dose) at which a certain percentage of cells would be alive or dead after being treated by 
the agent. In the case of establishment of stable cell lines, it is important to determine LD 
at which there is more than 90% mortality.  
2.2.6.7.1. Experimental setup 
To predict the concentration of puromycin required to kill ∼100% DG75 cells, a 
Completely Randomized Design (CRD) was used an experimental model.  CRD is a type 
of statistical experimental design that is equivalent to a t-test when only two treatments 
are examined. In this model, replications of treatments (concentration of puromycin) are 
assigned completely at random to independent experimental subjects (cells). Adjacent 
subjects could potentially have the same treatment.  
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Cells were plated in triplicates in a 6 well plate at a density of 5 × 104 cells per well. 
Except for control group, four different concentrations of puromycin were used: 500 
ng/µl, 750 ng/µl, 1000 ng/µl, 1250 ng/µl.  
2.2.6.7.2. Probit Analysis 
Data obtained was analyzed by SPSS® 15.0. Analysis was done by selecting Probit from 
the subcategories of Regression Analysis (RA) under the Analysis Toolbar. Probit is a 
specialized regression model of binomial response variables. The model tries to estimate 
a linear function that can approximate the sigmoid distribution.  
2.2.7. Transfection 
DG75 cells are normally hard to transfect with chemical tranfection agents. Method of 
choice is thus to use electric current to transfect the cells.  
2.2.8. Electroporation 
1 × 107 cells (in 50 ml flask) at mid log phase were used for the electroporation 
procedure. The cells were washed with 1× OPTIMEM. Cells were centrifuged at 500×g 
for 5 minutes. Supernatant was discarded and pellet was washed and mixed gently with 
1× OPTIMEM (4 – 6 times). Cells were further centrifuged at 500×g for 5 minutes. After 
discarding the supernatant, cells were diluted in 350 µl OPTIMEM. 5 µg of pINCO 
NGFR and 15 µg pRTS-1 constructs were co-electroporated (230 Volts and 1mF). 5% 
FCS (from 15% pre-warmed FCS) was added immediately after electroporation. 
2.2.8.1. Ficoll procedure 
After culturing the cells at 37oC (5% CO2) overnight, 30 ml of the supernatant out of 50 
ml was discarded. Cells were resuspended with the remaining media.  20 ml Ficoll was 
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very gently applied to the bottom of the 50 ml conical bottom tube without disturbing the 
overlay and gently moving up along the border of the Ficoll/medium boundary. Cells 
were spun in a swinging bucket rotor at 2000 rpm for 30 minutes with deceleration rate of 
1 rpm per second. Live cells form a ring at the interface between Ficoll and medium 
while dead cells settle to the bottom of the flask. The ring was pipetted very gently and 
mixed with 5 ml fresh medium and spun at 1500 rpm for 5 minutes in a swinging bucket 
rotor with deceleration rate of 1 rpm per second. Finally, the pellet was resuspended in 50 
ml fresh medium. 
2.2.8.2. Sorting NGF+ cells by MACS 
There is an optimal NGF expression in the transfected cells 2-3 days after transfection. 
To enrich for transfected cells, Magnetic-Activated Cell Sorting targeting the NGF was 
used. Approximately 40 ml of the 50 ml old medium was discarded (flasks were kept in 
standing position). Cells were resuspended with the remaining medium (approx. 10 ml). 
12.5 ml PBS plus MACS Buffer (2.5 g BSA/500 ml approx. 0.5%; 2 ml EDTA 0.5 M 
final concentration 2 mM) was added. Cells were spun at 500 × g for 5 minutes at 4°C 
(from here onwards, everything was carried out at 4°C). The following cocktails were 
prepared before the experiment started: 
Table 2.18. MACS cocktails 
Cocktail Volume Description 
anti NGF antibody mix 800 µl 720 µl of MACS Buffer and 80 µl 
of anti NGF antibody 
Goat anti mouse IgG microbeads 400 µl 360 µl Buffer and 40 µl beads 
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The supernatant was discarded and the pellet was resuspended in 400 µl anti NGF 
antibody mix and put at 4°C for 20 to 30 minutes. The sample was washed once with ice 
cold MACS buffer and kept at 4°C. It was later centrifuged at 500 × g for 5 minutes at 
4°C. Supernatant was discarded and 200 µl of Goat anti mouse IgG micro beads was 
added and mixed. The sample was left on ice for 20 minutes. 15 ml of MACS Buffer was 
added after the incubation and centrifuged at 500 × g at 4°C for 5 minutes. Following 
centrifugation, 500 µl ice cold MACS buffer was added to soften the beads. In the mean 
time, MACS columns were equilibrated with 3 ml MACS buffer. The 500 µl micro beads 
solution was added to the pre-equilibrated column and was filled up three times with 3 ml 
MACS buffer. The column was removed from magnet stand and put on a fresh 15 ml 
conical bottom falcon tube. 7 ml of MACS buffer was added and the column was plunged 
with strong force 4 times and the content was collected in the fresh 15 ml tube. This was 
further centrifuged at 500 × g for 5 minutes at 4oC. Finally, after discarding the 
supernatant, the pellet was solved in approximately 5 ml medium. 
2.2.9. Polymerase Chain Reaction (PCR) 
2.2.9.1. Traditional PCR 
Polymerase Chain Reaction is widely held as one of the most important inventions of the 
20th century in molecular biology. Small amounts of the genetic material can now be 
amplified to be able to a identify, manipulate DNA, detect infectious organisms, 
including the viruses that cause AIDS, hepatitis, tuberculosis, detect genetic variations, 
including mutations, in human genes and numerous other tasks. 
To perform several parallel reactions, master mix was prepared. It contains water, buffer, 
dNTPs, primers and Taq DNA Polymerase in a single tube, which was then be aliquoted 
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into individual tubes. Template DNA was finally added to individual tubes. Master mix 
preparation is described below. 
All solutions were gently vortexed and briefly centrifuged after thawing. In a thin-walled 
PCR tube put on ice, the following components were added: 
Table 2.19. Traditional PCR reaction mix 
Reagent Final concentration Quantity for 20 µl of reaction mixture  
Sterile deionized water  - variable 
10X Taq thermopol buffer 1X 2 µl 
10 mM dNTP mix 0.2 mM of each 0.4 µl 
Primer Top (10 µM) 0.025 µM 0.5 µl 
Primer Bottom (10 µM) 0.025 µM 0.5 µl 
Taq DNA Polymerase 0.5 u / 20 µl 0.125 µl 
Template DNA 10pg-1 µg variable 
 
The sample was gently vortexed and briefly centrifuged to collect all drops from walls of 
tube. Samples were placed in a thermo-cycler with the appropriate program and were run. 
2.2.9.2. Reverse Transcriptase PCR (RT-PCR) 
RT-PCR is a sensitive and reproducible method for the detection of RNA molecules. It is 
a two step process (see figure 1): 
a. Reverse transcription, a process by which DNA copies are made from RNA 
template (cDNA synthesis) 
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b. PCR/Amplification aims at amplifying sequences of interest from the library 
using gene/sequence specific primers 
 
Figure 2.1.  Schematic representation of the RT-PCR procedure (adapted from Invitrogen Inc.) 
 
cDNA synthesis: The following components were mixed in 1.5 ml microfuge: 
Table 2.20. RT-PCR first reaction mix (Primers, dNTPs and RNA) 
Component  Amount 
Primer (50 ng/μl)  1 μl 
RNA (10 pg -5 μg)  x μl 
10 mM dNTP Mix  2 μl 
DEPC-treated water  to 12 μl 
 
Materials and Methods 
58 
 
The mix was denatured by incubating at 65°C for 5 min and later placed on ice. 5X 
cDNA Synthesis Buffer was vortexed for 5 s just prior to use. Master reaction mix was 
prepared, as per the following composition, on ice and vortexed gently. 
Table 2.21. RT-PCR first strand synthesis mix 
Component  Amount 
5x cDNA Synthesis Buffer  4 μl 
0.1 M DTT  1 μl 
RNaseOUT. (40 U/μl)  1 μl 
DEPC-treated water  1 μl 
ThermoScript. RT (15 units/μl)  1 μl 
 
8 μl of master reaction mix was pipetted into each reaction tube on ice and transferred to 
a preheated thermal cycler with the following program: 25°C for 10 min, followed by 20-
50 min at 50°C (or 50-65°C). Reaction was terminated by incubating at 85°C for 5 min. 
Finally, 1 μl of RNase H was added and sample was incubated at 37°C for 20 min. 
Sample was stored at -20°C or used for PCR immediately. 
Amplification: PCR was carried out using Platinum® Taq DNA Polymerase High 
Fidelity. 10% of the cDNA synthesis reaction (2 μl) was used for PCR. The following 
components were mixed in a 0.2- or 0.5-ml, thin-walled, PCR tube: 
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Table 2.21. PCR mix for gene specific amplification from cDNA 
Component  Amount 
10X High Fidelity PCR Buffer 5 μl 
50 mM MgSO4 2 μl 
10 mM dNTP Mix 1 μl 
10 μM sense primer 1 μl 
10 μM antisense primer 1 μl 
Platinum® Taq High Fidelity 0.2 μl 
cDNA (from cDNA synthesis reaction) 2 μl 
DEPC-treated water 37.8 μl 
Final volume 50 μl 
 
Samples were mixed gently and put in a preheated thermocycler with the following 
settings: 
Table 2.22. PCR program setup for detection of CALM/AF10 from cDNA preparation 
Temperature Time Remark 
94°C 2 min Hold 
94oC 30 seconds  
54.7oC (temp depends on primers) 30 seconds 30 cycles 
68°C 1 min/kb extension  
68°C 7 minutes Final Extension 
4oC ∞ Hold 
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10 μl of the amplified sample was analyzed by agarose gel electrophoresis. 
2.2.10. Colony PCR 
This protocol is designed to quickly screen for plasmid inserts directly from E. coli 
colonies. This technique can be used to determine insert size and/or orientation in the 
vector. Colonies from successful ligation/transformation reaction were picked and 
cultured in LB medium with the appropriate selection agent overnight at 37oC in a shaker 
set to 230 rpm. 
The next day, the following ingredients were mixed on ice: 
Table 2.23. Reaction mix for colony PCR 
Component Amount 
sterile distilled water 38 μl 
10X PCR buffer 5 μl 
25 mM MgCl2 3 μl 
10 mM dNTPs (10 mM each dATP, dTTP, dGTP, dCTP) 1 μl 
20 μM forward primer 1 μl 
20 μM reverse primer 1 μl 
Taq polymerase 0.2-1 μl 
Total volume 50 μl 
 
To each cold PCR tube containing the PCR reaction, 1 μl from the overnight culture was 
added and mixed thoroughly. 
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Table 2.24. Program setup for colony PCR 
Temperature Time Remark 
95°C  5 min Lysis and denaturation 
95°C 1 min DNA denatures into single 
strands 
54°C (temp depends on primers) 1.5 min 30-40 cycles 
72°C 1 min (1 min/kb) primers are extended from 
3'-end by Taq 
72°C 5 min final extension 
4oC ∞ Hold 
2.2.11. Real Time PCR (Applied Biosystems 7900HT Micro Fluidic Card) 
The Micro Fluidic Card allows you to use the 7900HT system for profiling gene 
expression using the Comparative CT Method of relative quantification. The card 
evaluates from one to eight cDNA samples or controls generated from total RNA in a 
two-step RT-PCR. The following protocol describes, adopted with some modifications 
from Applied Biosystems 7900HT Micro Fluidic Card Getting Started 
Guide(Biosystems, 2003), the steps following post cDNA synthesis. 
2.2.11.1. Amount of cDNA in the PCR Mix 
Each 100 μl PCR mix, enough to fill one reservoir, contained 33.75 ng of total RNA 
converted to cDNA. The cDNA sample volume, with added water, was 50 μl. cDNA 
sample was thawed by rolling the tube between fingers. Sample was gently vortexed and 
centrifuged. The following components were added to a labeled 1.5-ml microcentrifuge 
tube: 
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Table 2.25. Sample reaction mix for Low Density Array real-time PCR 
Component Volume Per Fill Reservoir (μl) 
cDNA 0.75 
H2O 49.25 
TaqMan® Universal PCR Master Mix (2X) 50 
Total 100 
 
The micro-centrifuge tube was capped and thoroughly mixed by gentle vortexing. The 
tube was centrifuged to eliminate air bubbles from the mixture. The Micro Fluidic Card 
was loaded with samples as per the recommended guideline. 
Table 2.26. List of different LDA cards available from Applied Biosystems® 
TaqMan Low 
Density Array 
Number of 
Targets and 
Controls 
Number of 
Assay 
Replicates 
Number of 
Samples per 
Card 
Minimum 
Order Size 
Part Number 
Format 12 11 + 1 4 8 20 4342247 
Format 16 15 + 1 3 8 20 4346798 
Format 24 23 + 1 2 (4) 8 (4) 20 4342249 
Format 32 31 + 1 3 4 20 4346799 
Format 48 47 + 1 2 (4) 4 (2) 10 4342253 
Format 64 63 + 1 3 2 20 4346800 
Format 96a* 95 + 1 2 (4) 2 (1) 10 4342259 
Format 96b 95 + 1 2 (4) 2 (1) 20 4342261 
Format 384 380 + 1 1 1 50 4342265 
* Type of card used  
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Applied Biosystems provides 9 formats of Low Density Array (LDA) cards. Format 96a 
was used in this experiment. 95 genes that had been found to be differentially regulated 
were selected for the custom setup. The table above gives details about the types of cards 
available. 
Once samples were loaded, the fluidics card was centrifuged in a Heraeus centrifuge with 
bucket settings. The following table lists the operational parameters for Micro Fluidic 
Cards. 
Table 2.27. Centrifugation generic setup for LDA cards 
 
Parameter  
  
 
QUIKSet 
 
EASYSet 
Up ramp rate 3  
 
9 
Down ramp rate N/A  
 
9 
Rotational speed  
 
1200 rpm 1200 rpm 
Centrifugation time 2 × 1 min (0.01 on display) 
 
2 × 1 min (0.01 on display) 
 
 
Following centrifugation based on the above settings, the fluidics card was sealed and 
sample loader was trimmed. 
2.2.11.1. Program setup and run 
Sequence Detection Software version 2.1 (SDS 2.1) was used to run the fluidics cards 
and acquire data. Further data analysis was also performed using SDS 2.1. New template 
file was created using the options Relative Quantification (∆∆ Ct) and 384 well cards. 
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After a new document template has been created, the default thermal cycling conditions 
for Micro Fluidics Cards were set (See table below). 
Table 2.28. Applied Biosystems® 7900HT real-time PCR reaction instrument setup for LDA 
AmpErase UNG Activation AmpliTaq Gold DNA 
Polymerase Activation 
Each of 40 Cycles 
Melt Anneal/Extend 
50 °C 
 
94.5 °C 
 
97 °C 
 
59.7 °C 
 
2 min 
 
10 min 
 
30 sec 
 
1 min 
 
100% ramp 
 
100% ramp 
 
50% ramp 
 
100% ramp 
2.2.12. Microarray Analysis 
This protocol is a summary of the extensive protocol provided by 
Affymetrix(Affymetrix, 2005). Further details are found in the complete standard 
operation manual (Figure 2.2 summarizes the workflow). The procedure requires a 
minimum of 5 μg of purified total RNA as starting material. 
2.2.12.1. First-Strand cDNA Synthesis 
5 μg of total RNA was added to a 1.5-ml RNase-free tube and mixed with 1 μl of 100 
pmol/μl T7-(dT)24 primer. Volume was adjusted to 12 μl /reaction with nuclease-free 
water. The mix was incubated at 65 °C for 10 minutes and centrifuged briefly at about 
10,000 rpm for 10 sec and placed on ice. 4 μl of 5X first-strand cDNA buffer, 2 μl of 0.1 
M dithiothreitol (DTT), and 1 μl of 10 mM dNTP mix were added and mixed well. The 
sample was incubated at 42 °C for 2 min. Following the addition of 1 μl of 200 U/μl 
SuperScript II RT, the mix was further incubated at 42 °C for 1 hr and finally centrifuged 
briefly at about 10,000 rpm for 10 sec and placed on ice. 
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Figure 2.2. (a) A set of short oligonucleotides matching to different parts of an mRNA reference 
sequence is designed and is referred to as a probeset. A probeset contains pairs of 
oligonucleotides that either perfectly match (Perfect Match probe, PM) or contain a single 
mismatch (MisMatch probe, MM, serving as negative control) to the reference mRNA. (b) 
Affymetrix microarray workflow (both images adapted from 
http://www.dkfz.de/gpcf/24.html). 
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2.2.12.2. Second-Strand cDNA Synthesis 
30 μl of 5x second-strand reaction buffer, 3 μl of 10 mM dNTP mix, 1 μl of 10 U/μl E. 
coli DNA ligase, 4 μl of 10 U/μl DNA polymerase I, 1 μl of 2 U/μl RNase H, and 91 μl of 
nuclease-free water were added to the first strand cDNA synthesis reaction and incubated 
at 16 °C for 2 hrs. 2 μl of 5 U/μl T4 DNA polymerase was added and the mix was further 
incubated at 16 °C for 5 min. 10 μl of 0.5 M EDTA was added prior to proceeding to 
cleanup and precipitation.  
2.2.12.3. cDNA Cleanup and Precipitation 
600 µl of cDNA binding buffer (from GeneChip Sample Cleanup Module) was added to 
the synthesized cDNA. The sample was applied to a cDNA cleanup spin column sitting 
in a 2-ml collection tube and centrifuged at 8000 x g for 1 min. The flow-through was 
discarded. The collection tube was replaced with another 2-ml collection tube. 750 µl of 
cDNA wash buffer was added to the spin column and centrifuged at 8000 x g for 1 min. 
The flow-through was again discarded.21. The spin column was centrifuged at maximum 
speed for 5 min with the column cap opened. The column was transferred to a fresh 1.5-
ml collection tube and 14 µl cDNA elution buffer was pipetted directly onto the column 
membrane. Centrifuge at 8000 x g for 1 min to elute DNA. 
2.2.12.4. Biotin-Labeled cRNA Synthesis 
10 µl of sample cDNA, 4 µl of 10x HighYield (HY) reaction buffer, 4 µl of biotin-
labeled ribonucleotides, 4 µl of DTT, 4 µl of RNase inhibitor mix, and 2 µl of 20x T7 
RNA polymerase were mixed with nuclease-free water to provide a final reaction volume 
of 40 µl. The mix was incubated at 37oC for 5 hr. For cleanup and quantification, the 
sample volume was adjusted to 100 µl with nuclease-free water and 350 µl of IVT cRNA 
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binding buffer was added and mixed well by pipetting. 250 µl of 100% ethanol was 
added and mixed well by pipetting gently 4 to 5 times. Sample was applied to an IVT 
cRNA cleanup spin column sitting in a 2-ml collection tube and centrifuged at  8000 x g 
for 15 sec. The column was transferred to a fresh collection tube and 500 µl IVT cRNA 
wash buffer was added. Further centrifugation was carried out at 8000 x g for 15 sec. The 
flow-through was discarded and the column returned to same collection tube. 500 µl of 
80% ethanol was added and centrifuged at 8000 x g for 15 sec. The spin column was 
centrifuged at maximum speed for 5 min with the column cap opened to dry the column 
membrane. The column was transferred to a fresh 1.5-ml collection tube and 25 µl of 
nuclease-free water was pipetted directly onto the column membrane and centrifuged at 
25,000 x g for 1 min to elute RNA. The RNA yield was determined by 
spectrophotometric analysis, applying the convention that 1 OD at 260 nm equals 40 
µg/ml RNA.  
2.2.12.5. cRNA Fragmentation 
8 µl of 5x fragmentation buffer was added to 20 µg of cRNA and the total volume was 
brought to 40 µl with nuclease-free water. The mix was incubated at 94°C for 35 min and 
placed on ice. 
2.2.12.6. Array Hybridization 
10 µg of fragmented cRNA was mixed with 3.3 µl of 3 nM control oligonucleotide B2, 
10 µl of 20X eukaryotic hybridization control, 2 µl of 10 mg/ml herring sperm DNA, 2 µl 
of 50 mg/ml acetylated BSA, 100 µl of 2X hybridization buffer, and nuclease-free water 
to a final volume of 200 µl. The probe array was equilibrated to room temperature before 
use. The hybridization mixture was incubated at 99°C for 5 min. In the meantime, the 
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probe array was filled with 160 µl of 1X hybridization buffer and incubated at 45°C for 
15 min. The buffer was removed from the probe array and the array was filled with 200 
µl of hybridization mixture. The filled array was placed in a rotisserie box heated to 45°C 
for 16 hrs. 
2.2.12.7. Array Post-Hybridization Washing 
All required buffers and staining reagents, including nonstringent wash buffer, stringent 
wash buffer, streptavidin-phycoerythrin (SAPE) stain solution, and antibody solution mix 
were prepared prior to washing procedure. The Fluidics Station was turned on. From the 
Microarray Suite, the Fluidics option was run. The Fluidics Station was primed by 
selecting Protocol  Prime from the drop-down menu. 
The nonstringent wash buffer was placed in reservoir A while the stringent wash buffer 
was placed in reservoir B. The nuclease-free was poured into the water reservoir. Run 
was executed to begin priming. Experiment file for each probe array was created by 
clicking Run  Experiments Info. The hybridization mixture was transferred from the 
probe array to a tube. The probe array was fully loaded with 160 µl of nonstringent wash 
buffer. From the Fluidics window, the drop-down menu below Experiment was clicked to 
select the correct experiment name; the drop-down menu below Protocol was also 
clicked to select the appropriate protocol. Once the setup was done, Run command was 
executed to begin washing and staining. The instructions on the monitor were followed 
and the probe array was inserted when prompted. The microcentrifuge tube was removed 
from the sample holder of the Fluidics Station. A microcentrifuge tube containing 600 µl 
of SAPE stain solution was placed in the sample holder. Further instructions on the 
monitor were followed and when prompted, the microcentrifuge with the staining 
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solution was replaced with a microcentrifuge tube containing 600 µl of antibody solution 
mix. Furthermore, another microcentrifuge tube containing 600 µl of SAPE stain solution 
was put in place after being prompted for it. The Fluidics Station was allowed to continue 
until the EJECT CARTRIDGE message appeared on the monitor, indicating the 
completion of the protocol. The probe array was removed from the GeneChip Fluidics 
Station for scanning protocol. 
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III. Results 
3.1. Cloning experiments 
3.1.1. Cloning of FLAG-CALM/AF10 into the pUC19 Shuttle Vector 
The CALM/AF10 fusion gene that was used for this work was a FLAG-CALM/AF10 open-
reading frame (ORF) that was cloned in the pEYFP vector using XbaI and XhoI (Figure 3.1b).  
pEYFP vector doesn’t contain the appropriate restriction site (SfiI site) required to clone 
CALM/AF10 into the desired conditional mammalian expression vector pRTS-1 (Figure 3.3a 
and 3.3b). To facilitate the cloning procedure, FLAG-CALM/AF10 was first cloned into a 
shuttle vector that contains SfiI cassette (pUC19 vector). 
The XbaI and XhoI sites were used to clone FLAG-CALM/AF10 ORF into the plasmid 
pUC19 SfiI Shuttle Vector (Figure 1a). CALM/AF10 was cut out from the pEYFP vector 
backbone by using XhoI, XbaI, and NsiI (Figure 3.1c, lanes 7 to 10). The pUC19 Shuttle 
Vector was digested with XhoI and XbaI (Figure 3.1c, lanes 1 to 5). 
3.1.2. Cloning of VP16 upstream of FLAG-CALM/AF10 
The VP16 transactivating domain, a strong transactivating domain which is able to 
transactivate almost all promoter types, was cloned up-stream and in-frame to the 
CALM/AF10 fusion protein in order to convert CALM/AF10 from a transcriptional 
repressor into a strong transcriptional activator of these promoters thus leading to a clear 
detection of genes, in the microarray analysis, that are normally down-regulated by 
CALM/AF10. It should be noted that this is an additional clone. The transactivation 
domain of VP16 (tVP16) cloning was carried out by first amplifying the tVP16 from the 
pVP-FLAG vector by adding NotI and XhoI sites to the forward and reverse primers, 
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respectively. These restriction sites were later used for cloning the tVP16 into the 
pUC19-FLAG-CALM/AF10 construct (Fig 3.1a and 3.1b). 
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Figure 3.1. Cloning of FLAG-CALM/AF10 into the pUC19 shuttle vector. (a) the pUC19 shuttle 
vector  (b) pEYFP-FLAG-CALM/AF10 (c) Agarose gel showing the fragments produced by the 
restriction digestion, arrows indicating desired fragments. M is the DNA ladder used and 
fragment sizes are given on the left and right hand side of the gel (in kbp). 
 
 
 
 
 
 
 
 
 
Figure 3.2. Schematic diagram of the pVP-FLAG vector containing the VP16 transactivating 
domain (a). Diagram (b) and gel (c) showing the PCR product and size. M is the DNA ladder 
used and fragment sizes are given on the left hand side of the gel (in bp). 
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3.1.3. Cloning of FLAG-CALM/AF10 and FLAG-VP16-CALM/AF10 into pRTS-1 
pRTS-1 is an EBV-derived episomally replicating plasmid that carries all the elements 
for conditional expression of a gene of interest via Tet regulation. The vector is 
characterized by  
(i) low background activity,  
(ii) high inducibility in the presence of doxycycline (Dox) and  
(iii) graded response to increasing concentrations of the inducer (Bornkamm et 
al., 2005).  
The gene of interest is expressed from the bidirectional promoter Ptetbi-1 that allows 
simultaneous expression of two genes, of which one may be used as surrogate marker for 
the expression of the gene of interest. Tight down regulation is achieved through binding 
of the silencer tTSKRAB to Ptetbi-1 in the absence of the inducer (e.g. Doxycycline, 
Dox). Addition of Dox releases repression and via binding of rtTA2S-M2 activates the 
promoter Ptetbi-1. pRTS-1 has the GFP gene on one side of the promoter and the firefly 
luciferase gene on the other. Two SfiI sites flank the luciferase gene. 
VP16-FLAG-CALM/AF10 and FLAG-CALM/AF10 (without VP16) were cloned into 
pRTS-1 using SfiI restriction sites (Figure 3.3c). SfiI has a bipartite recognition sequence 
(two 4 nucleotide sequences) flanking a core of 5 not-defined nucleotides. The enzyme 
creates a 3 nucleotide long 3′ overhang in this non -defined internal pentanucleodtide. 
DNA fragments cut with SfiI will only religate if the 3 nucleotides of this 3′ overhang are 
complementary, which is the case in for the SfiI sites in the pUC19-SfiI shuttle vector and 
pRTS-1. This allows the easy directional cloning of fragments from the pUC19-SfiI 
shuttle into the pRTS-1 vector. 
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Figure 3.3. (a) Schematic diagram of pRTS-1 expression vector, (b) illustration showing how 
the bidirectional promoter works, (c) Agrose gels showing the pRTS-1 backbone (upper bands) 
and Luciferase (lower bands) after SfiI digestion (Left gel, lanes 3 and 4). Lanes 1 and 2 in the 
same gel show SfiI digested FLAG-CALM/AF10 and VP16-FLAG-CALM/AF10 (upper bands), 
respectively, the lower bands are the vector backbone of pUC19 Shuttle Vector.  Right gel 
(lanes 1 to 3) shows SfiI digestion upon successful cloning of CALM/AF10 (lower bands) into 
the pRTS-1 vector (upper bands). M is the DNA ladder used and fragment sizes are given on 
the left and right hand sides of the gels (in kbp). 
 
3.2. Establishing a stably transfected cell line 
There are many different approaches for establishing stable cell lines, depending on the 
type of expression one is interested in (inducible vs. constitutive) and the construct to be 
used. The desired end result is a population of cells in which > 95% of the cells are 
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expressing the protein of interest at approximately the same level. This allows large-scale 
biochemical analyses of the protein and monitoring of localization throughout the cell 
cycle, and greatly simplifies many other microscopy techniques as well (Lamond, 2008). 
DG75 is a human Burkitt lymphoma cell line that was originally established from the 
pleural effusion of a 10-year-old boy with Burkitt lymphoma in 1975 (Ben-Bassat et al., 
1977). It has a near diploid karyotype with a t(8;14) with 6% polyploidy - 46XY, 
t(8;14)(q24;q32).  
3.2.1. Electroporation/transfection 
Electroporation was carried out as per the protocol described in the materials and 
methods section. DG75 cells were transfected with the following vectors and constructs: 
Table 3.3. Type of constructs/vectors and amount of DNA used for the electroporation procedure 
Construct/Vector Amount used per 
1 × 107 cells 
Remark 
pRTS-1-FLAG-CALM/AF10 15 µg Co-transfected with 5 µg of NGFR* 
expressing vector (pINCO) 
pRTS-1-VP16-FLAG-CALM/AF10 15 µg Co-transfected with 5 µg of NGFR 
expressing vector (pINCO) 
pRTS-1 vector backbone 15 µg Co-transfected with 5 µg of NGFR 
expressing vector (pINCO) 
* Nerve Growth Factor Receptor 
The electroporation resulted in about 40% of cell death. After collecting the live cells 
using Ficoll and culturing them for 48 hours, Magnet Assisted Cell Sorting (MACS) was 
carried out using antibodies against the NGFR, a membrane protein that is expressed by 
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the co-electroporated expression vector pINCO. It takes approximately 48 hours for 
sufficient NGFR to be present on the membrane of the cells for MACS. 
Cells were cultured for an additional 48 hours and were then induced with doxycycline (1 
µg/ml) and then the percentage of GFP positive cells was analyzed by flow cytometry. 
The following table shows the proportion of GFP positive cells for the different 
transfections: 
Table. 3.2. Percentage of GFP positive cells after transfection. 
Construct/Vector % GFP Positive Remark 
pRTS-1-FLAG-CALM/AF10 20 Result after NGFR sorting 
pRTS-1-VP16-FLAG-CALM/AF10 18 Result after NGFR sorting 
pRTS-1 vector backbone 17 Result after NGFR sorting 
3.2.2. Selection/enrichment of transfected cells 
Puromycin has been used as a selection agent to enrich transfected DG-75 cells. pRTS-1 
contains a gene that encodes puromycin resistance enzyme which is constitutively 
expressed independent of the inducible bi-directional promoter that controls the GFP and 
CALM/AF10. As a result, the enrichment of transfected cells can be performed without 
inducing the cells.  
Puromycin dihydrochloride is an aminonuclease antibiotic that inhibits protein synthesis. 
Puromycin is used for selection and maintenance of cell lines expressing a transfected 
Pac gene, whose product, puromycin acetyltransferase, inactivates puromycin via 
acetylation. The working puromycin concentration for mammalian cell lines ranges from 
1-10 µg/ml. The selection agent needs to be titrated prior to use to determine the optimal 
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concentration for the target cell line. Normally, the lowest concentration that kills 100% 
of non-transfected cells in 3-5 days from the start of puromycin selection at an average 
cell density of 6 × 104 cells/ml is used. 
Depending on individual cell type and doubling rate, the selection of stable transfectants 
will take between 7 and 28 days. The expansion and characterization of single cell clones 
will take several weeks in addition. The media should be changed every 2-3 days. This 
eliminates potentially toxic substances produced by dying cells and it keeps the 
concentration of the antibiotic at a constant level.  
To calculate the concentration of puromycin to use for the enrichment of transfected DG-
75 cells, non-transfected DG-75 cells were seeded on a six well plate and each well was 
treated with one specific concentration of puromycin by following Completely 
Randomized Design (CRD) strategy. The position of replicates (well number) and the 
concentration of puromycin (treatment) applied was randomized in each plate. 
The Mortality rate was estimated 5 days after treatment by counting dead/live cells after 
staining for Trypan blue. Appendix A1 details the result obtained, adjusting the natural 
mortality rate observed in control cells to 0 percent mortality (100% survival). 
Based on these results (see Appendix A5), we used a concentration of 1.24 µg/ml 
puromycin to achieve a close to 100% kill of non transfected cells within 5 days at a cell 
density of 6 × 104 cells/ml. 
3.2.3. Conditional expression 
Once the required dose of puromycin had been determined, the cells were put under 
selection at a density of 6 × 104 cells/ml and monitored every week for selection 
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efficiency. In the first 10 days, a strong enrichment of transfected cells was observed. 
Table 3.3 shows results obtained after 10 days selection. Cell samples were analyzed by 
flow cytometry 24 hours after GFP expression had been induced with doxycycline (1 
µg/ml). 
Table 3.3. Percentage of GFP positive cells after 10 days of puromycin selection 
Construct/Vector % GFP Positive Remark 
pRTS-1-FLAG-CALM/AF10 60 Result after 10 days puromycin 
selection 
pRTS-1-VP16-FLAG-CALM/AF10 65 Result after 10 days puromycin 
selection 
pRTS-1 vector backbone 57 Result after 10 days puromycin 
selection 
 
Fluorescent microscopic observation was also carried out for the expression of GFP and 
visual assessment of induction. Figure 3.4 shows these observations for both the FITC 
(channel showing only GFP expressing cells) and phase contrast (all cells) modes. 
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Figure 3.4. GFP expression after induction by Doxycycline. DG-75 cells expressing FLAG-
CALM/AF10 (from the pRTS-1-FLAG-CALM/AF10 construct) (24 hours after induction, 1 
µg/ml doxycycline). Left image: FITC, 20 X magnifications; Right image: No fluorescence filter, 
20 X magnifications. 
3.3. RT PCR 
Once the desired percentage of GFP positive cells was obtained (> 90%, after 4 weeks of 
puromycin selection), the expression of CALM/AF10 was confirmed by RT-PCR. 
RNA extracted from induced DG75 cells was used as a starting material. 3µg of total 
RNA was treated with DNaseI to remove DNA contamination. Approximately 900 ng of 
DNaseI treated total RNA was used for cDNA synthesis using random primers and the 
protocol provided by Invitrogen (Materials and Methods section 2.2.10.2) for the 
Thermoscript RT-PCR kit. 
A CALM/AF10 specific primer set was used to confirm the expression of CALM/AF10 
after induction. The CALM/AF10 primers used were: Forward 5′ -
GCAATCTTGGCATCGGAAAT-3′ (Forward) and 5′-GCCTGTCGACATCCATGTTT-
3′ (Reverse) (a schematic representation of the binding site of the primers in 
CALM/AF10 and the amplified fragment is shown in Figure 3.5a). The primers were 
designed to amplify across the breakpoint to ensure that the primers are amplifying the 
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fusion gene and not the endogenous forms of either CALM or AF10. The RT-PCR 
amplified the expected products (Figure 3.5b).  
 
Figure 3.5. (a) Schematic representation of the binding sites of the primers used and the part 
of CALM/AF10 that they amplify (yellow-shaded area) (b) RT-PCR result. Lanes 1 and 6 are 
negative control (H2O); Lane 2 = pRTS-1 vector only control (non-induced); Lane 3 = pRTS-1 
vector only control (24 hours after induction); Lane 4 = pRTS-1-FLAG-CALM/AF10 (non-
induced); Lane 5 = pRTS-1-VP16-FLAG-CALM/AF10 (non induced); Lanes 7 and 8 are pRTS-1-
FLAG-CALM/AF10 (24 hours after induction); Lanes 9 and 10 are pRTS-1-VP16-FLAG-
CALM/AF10 (24 hours after induction). M is the DNA ladder used and size markers are 
indicated by numbers on the left side of the gel (in kbp). 
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3.4. Microarray 
3.4.1. Experimental Setup 
RNA samples, that were obtained from induced and non-induced cells and were 
confirmed for the expression of CALM/AF10 by RT-PCR, were used as a starting 
material for the microarray experiment. 
Each sample obtained was applied to one HGU133 Plus 2.0 Affymetrix gene chip array 
by employing the protocol detailed in the materials and methods section. Scanned array 
images were finally stored as .CEL files. 
3.4.2. Low-level Analysis of Microarray Data 
3.4.2.1. Preprocessing and Normalization 
Since scanned images may have different overall brightness, generally the normalization 
is needed to adjust the brightness of the arrays to comparable level. Currently, there are at 
least 6 popular algorithms that can normalize microarray data using different 
mathematical approaches (Millenaar et al., 2006). Recently, more methods have become 
available for calculating gene expression values, such as Model-Based Expression 
Indexes (MBEI) from Li and Wong (Li and Wong, 2003) that are implemented in the 
freeware program dChip. Also available is the Robust Multiarray Average (RMA) 
software from Irizarry et al. (Irizarry et al., 2003). In contrast to MAS 5.0 or GCOS, in 
which information from only one microarray is used, model-based algorithms incorporate 
information from multiple microarrays to calculate the expression of a gene. The probe 
response pattern is fitted over multiple arrays with a multiplicative model in dChip and an 
additive model in the RMA software. These algorithms use the fitted models to detect 
abnormally behaving probes, which are subsequently excluded for calculating gene 
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expression. Therefore, gene expression from these model-based algorithms can be 
expected to provide more reproducible results. Both dChip and RMA use a stochastic 
model to estimate gene expression.  
3.4.2.1. Median Probe Intensity (MPI) and background Adjustment 
dChip (Li and Wong, 2003), a freely available software 
(http://biosun1.harvard.edu/complab/dchip/), was used to perform the normalization of 
the microarray data obtained. dChip normalizes arrays at the Perfect Match (probes 
matching perfectly to a certain part of the reference mRNA, PM) and Mismatch (probes 
containing a single mismatch, MM) (see figure 2.2a) probe level before computing 
model-based expression levels. Model-based method assumes that the arrays are already 
at comparable brightness (Li and Wong, 2003). However, there is also a danger of 
introducing artifacts if normalization is not done reasonably. To avoid the introduction of 
artifacts, one can examine the normalization curve and, if the amplification and scanning 
steps are controlled well and if the median intensities of arrays are close (± 5 Median 
Probe Intensity (MPI) from the median array), one may skip the normalization step and 
perform a model-based expression analysis directly (Li and Wong, 2003). It is very 
critical that a visual inspection of the array images is performed before further analysis is 
carried out to rule out artifacts.  
Table 3.4 summarizes the names of the arrays and the median intensities obtained for the 
arrays in this study. After the calculation of the Median Probe Intensities (MPI), it was 
observed that the array with median intensity (taking all the nine arrays together) was 
pRTS-1-FLAG-CALM/AF10 24hrs (MPI = 80). This array was then used as a baseline 
for the normalization of the remaining 8 arrays, a process by which the brightness of each 
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array is adjusted to approximate the MPI of the baseline array. The adjusted MPI values 
are given in Table 3.4. 
Table 3.4. Arrays and their Median Probe Intensity (MPI) 
Name of Array Median Probe Intensity (Brightness) Remark 
 Before Adjustment After Adjustment  
pRTS-1 0hrs 78 80 Sample from DG-75 transfected with 
the empty pRTS-1 vector (non-
induced) 
pRTS-1 24hrs 78  81 Sample from DG-75 transfected with 
the empty pRTS-1 vector (24 hours 
after induction) 
pRTS-1 72hrs 98 80 Sample from DG-75 transfected with 
the empty pRTS-1 vector (72 hours 
after induction) 
pRTS-1-VP16-FLAG-
CALM/AF10 0hrs 
95 80 Sample from DG-75 transfected with 
the VP16-FLAG-CALM/AF10-pRTS-1 
construct (non-induced) 
pRTS-1-VP16-FLAG-
CALM/AF10 24 hrs 
70 80 Sample from DG-75 transfected with 
the VP16-FLAG-CALM/AF10-pRTS-1 
construct (24 hours after induction) 
pRTS-1-VP16-FLAG-
CALM/AF10 72hrs 
85 80 Sample from DG-75 transfected with 
the VP16-FLAG-CALM/AF10-pRTS-1 
construct (72 hours after induction) 
pRTS-1- FLAG-
CALM/AF10 0hrs 
82  81 Sample from DG-75 transfected with 
the FLAG-CALM/AF10-pRTS-1 
construct (non-induced) 
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pRTS-1- FLAG-
CALM/AF10 24hrs 
80 80 Sample from DG-75 transfected with 
the FLAG-CALM/AF10-pRTS-1 
construct (24 hours after induction) 
NB: median Brightness across arrays 
pRTS-1- FLAG-
CALM/AF10 72hrs 
77  79 Sample from DG-75 transfected with 
the FLAG-CALM/AF10-pRTS-1 
construct (24 hours after induction) 
 
3.4.2.2. The Invariant Set Normalization 
The Invariant Set Normalization method chooses a subset of PM probes with small 
within-subset rank difference in the two arrays, to serve as the basis for fitting a 
normalization curve (Li and Wong, 2001). The image of outliers (array and single 
outliers) identified through model-fitting can be used to assess the quality of an 
experiment and to identify unexpected problems such as misaligned corner of a DAT file 
(Li and Wong, 2001). 
The fitted curve is the running median curve in the scatterplot of probe intensities of two 
arrays (with the baseline array on the Y-axis and the array to be normalized on the X-
axis). When fitting the running median curve at the two ends, 5% of the “invariant” 
points are used to fit a ray at one end fixed; this makes the high-end normalization 
relationship more smooth and robust. The final running median curve is a piece-wise 
linear curve (Li and Wong, 2001). Then the normalization transformation is performed 
for all the points (probes) in the array on the X-axis (the Y-axis is the baseline array and 
is not changed). To obtain the normalized value of a point which has a particular intensity 
value on the X-axis, we drop an imagined vertical line passing this point, and use the Y-
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axis value of the intersection point of this line and the fitted curve as the normalized 
value. The normalized probe values beyond the range [0, 65535] are truncated at the 
boundaries. The total effect of the normalization is a rotation and straightening of the 
scatter plot, so it better centers around the diagonal line y = x (Li and Wong, 2001). 
Figure 3.6 gives an example of an invariant set normalization carried out on pRTS-1 0hrs 
by using the baseline array pRTS-1-FLAG-CALM/AF10 24hrs.  
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Figure 3.6. Example of Invariant set normalization (pRTS-1 0hrs versus pRTS-1-FLAG-
CALM/AF10 24hrs). Y axes represent the base line array (pRTS-1-FLAG-CALM/AF10 24hrs) 
and X axes represent the array to be normalized (pRTS-1 0hrs in this case). Each black point 
indicates a probe intensity value. (a) Scatterplot of raw intensities as read by the Affymetrix 
array scanner. The invariant set (5 % of the points that are used to fit a ray that is fixed at 
one end) are indicated in red circles.  Blue indicated fitted function y=x (y equals to the raw 
intensity of the baseline array, pRTS-1-FLAG-CALM/AF10 24hrs). The green line represents the 
line that best describes the correlation of raw probe intensities of the base line array (pRTS-1-
FLAG-CALM/AF10 24hrs)and the array to be normalized(pRTS-1 0hrs) (correlation coefficient 
r = 0.957). (b) Normalized probe intensities. The probe intensities of the array to be 
normalized (pRTS-1 0hrs) are rotated to fit into the function y=x (by rotating the green line to 
fit the blue line) without changing the values of the base line (pRTS-1-FLAG-CALM/AF10 
24hrs) probe intensities.  
All the other arrays were normalized in a similar fashion by taking the pRTS-1-FLAG-
CALM/AF10 24hrs array as a base line array. 
3.4.3. High-level analysis 
3.4.3.1. Sample comparison (t-test) 
Given two samples or two groups of samples, we want to identify genes that are reliably 
differentially expressed between the two groups. This is done for every gene in the array and is 
based on calculating a t-statistic. The t-statistic tries to account for the level of difference in 
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expression of a given probe set in two different samples and determines if this difference 
is statistically significant (Li and Wong, 2003). 
Based on the t-test comparison of the different samples, various comparisons were 
carried out to find genes that are significantly differentially regulated at a confidence 
interval of 95%. The comparison was done by comparing the expression level of a 
probeset of a given gene in the experimental setting versus the expression level of the 
same probeset in the control setting. For instance, to find the genes that were at least 2 
fold significantly differentially regulated (up or down) in the sample pRTS-1-FLAG-
CALM/AF10 24 hrs (genes that were deregulated 24 hours after CALM/AF10 
expression), the pRTS-1-FLAG-CALM/AF10 24 hrs array was compared to the pRTS-1-
FLAG-CALM/AF10 0hrs (no CALM/AF10 expression) control. This list of differentially 
regulated genes was further subjected to other controls; genes that were also found to be 
2 fold differentially regulated in the following comparisons were excluded from the final 
list, 
a. pRTS-1-FLAG-CALM/AF10 0hrs to pRTS-1 0hrs (to exclude genes that were 
already 2 fold up or down-regulated without induction) 
b. pRTS-1 24 hrs to pRTS-1 0hrs (to exclude genes that were deregulated 
because of confounding factors like GFP expression or addition of 
doxycycline) 
Table 3.5 gives the number of genes that were found to be at least 2 fold significantly 
differentially regulated (up or down regulated) for different comparisons upon the 
expression of CALM/AF10. The genes that have fulfilled the selection criteria and test 
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statistics for were also evaluated by plotting them in an M (Intensity Ratio)-A (Average 
Intensity) plot (Figure 3.7). 
Table 3.5. Number of differentially regulated genes in different comparisons. 
Comparison 
number 
Experiment Baseline Number of 
genes 
1 pRTS-1-FLAG-CALM/AF10 24 hrs pRTS-1 0hrs, pRTS-1-FLAG-
CALM/AF10 0hrs, pRTS-1 24 hrs  
1237 
2 pRTS-1-FLAG-CALM/AF10 72 hrs pRTS-1 0hrs, pRTS-1-FLAG-
CALM/AF10 0hrs, pRTS-1 72 hrs 
564 
3 pRTS-1-VP16-FLAG-CALM/AF10 24 
hrs 
pRTS-1 0hrs, pRTS-1-VP16-
FLAG-CALM/AF10 0hrs, pRTS-1 
24 hrs 
990 
4 pRTS-1-VP16-FLAG-CALM/AF10 72 
hrs 
pRTS-1 0hrs, pRTS-1-VP16-
FLAG-CALM/AF10 0hrs, pRTS-1 
72 hrs 
164 
5 pRTS-1-FLAG-CALM/AF10 24hrs and 
pRTS-1-FLAG-CALM/AF10 72 hrs 
pRTS-1 0hrs, pRTS-1-FLAG-
CALM/AF10 0hrs, pRTS-1 24 hrs, 
pRTS-1 72 hrs 
477 
6 pRTS-1-VP16-FLAG-CALM/AF10 24hrs 
and pRTS-1-VP16-FLAG-CALM/AF10 
72 hrs) 
pRTS-1 0hrs, pRTS-1-VP16-
FLAG-CALM/AF10 0hrs, pRTS-1 
24 hrs, pRTS-1 72 hrs 
130 
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Figure3.7. M-A plot for identification of genes that are 2 fold differentially regulated in pRTS-
1-FLAG-CALM/AF10 24hrs. M (y axis) is the intensity ratio given by the log2 difference of the 
experimental sample (pRTS-1-FLAG-CALM/AF10 24hrs) and control (pRTS-1 0hrs, pRTS-1-
FLAG-CALM/AF10 0hrs, and pRTS-1 24hrs)(see text for explanation on how the comparison 
criteria is setup), and it is of the form M = log2E – log2C, where E is experimental sample and C 
is control. A (y=x line) is the average intensity for a probeset in the plot and is calculated using 
the formula A = ½ (log2E+log2C), where E and C are experimental expression level and control 
expression level, respectively. Red squares are probeset that satisfied the selection criteria (up 
and down-regulated) and blue dots are probesets that are not differentially regulated.  
3.4.3.2. The effect of the VP16 transactivating domain 
The VP16 transactivating domain is a strong transactivating domain which is able to 
transactivate almost all promoter types. We speculated that CALM/AF10 might act as a 
transcriptional repressor on certain promoters. However, due to limitations inherent in 
our experimental set-up (e.g. not 100% of cells transfected), weakly down-regulated 
genes would be more difficult to identify. To circumvent this problem, we fused the 
VP16 transactivation domain to the CALM/AF10 fusion protein in order to convert 
CALM/AF10 from a transcriptional repressor into a strong transcriptional activator of 
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these promoters thus leading to a clear detection of genes that would be normally down-
regulated by CALM/AF10. 
To assess whether VP16 had the expected effect, the list of genes that were found to be 
differentially regulated in pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG 
CALM/AF10 72hrs (Table 3.5, 5th comparison, 477 genes) were compared to the list of 
differentially regulated genes in pRTS-1-VP16-FLAG-CALM/AF10 24hrs and pRTS-1-
VP16-FLAG CALM/AF10 72hrs (Table 3.5, 6th comparison, 130 genes). It was observed 
that 95 of the 130 genes that were differentially regulated in pRTS-1-VP16-FLAG-
CALM/AF10 24hrs and pRTS-1-VP16-FLAG-CALM/AF10 72hrs (VP16-CALM/AF10 
expressing cells) were also differentially regulated in pRTS-1-FLAG-CALM/AF10 24hrs 
and pRTS-1-FLAG CALM/AF10 72hrs (CALM/AF10 expressing cells but without 
VP16). A Pearson correlation was used to evaluate whether the differential expression 
levels of these genes in these settings were comparable. The correlation analysis showed 
that there was a statistically significant correlation between the differential expression 
levels of genes in VP16-CALM/AF10 expressing cells and CALM/AF10 expressing cells 
but without VP16 (r=0.959, p ≈ 0.00) (Table 3.6 and figure 3.8). In conclusion, the VP16 
transactivating domain did not enhance genes that were found to be down-regulated in 
the pRTS-1-FLAG-CALM/AF10 (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-
FLAG CALM/AF10 72hrs) to control (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, 
pRTS-1 24hrs, and pRTS-1 72hrs) comparison.  
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Table 3.6. Correlation table comparing differential expression levels of VP16-CALM/AF10 expressing cells (pRTS-1-VP16-FLAG-CALM/AF10 24hrs and pRTS-1-VP16-FLAG-CALM/AF10 72hrs) and CALM/AF10 expressing cells but without VP16 (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG CALM/AF10 72hrs). 
 
 All time points taken together   CALM/AF10 
expressing cells but 
without VP16 
VP16-CALM/AF10 expressing cells Pearson Correlation .959(**) 
  Sig. (2-tailed) .000 
  N 95 
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Scatterplot showing fold expression levels of the 95 genes that were found to be 
differentially regulated in both VP16-CALM/AF10 expressing cells (pRTS-1-VP16-FLAG-
CALM/AF10 24hrs and pRTS-1-VP16-FLAG-CALM/AF10 72hrs, y axis) and CALM/AF10 
expressing cells but without VP16 (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG 
CALM/AF10 72hrs, x axis). Error bars indicate the 95% confidence interval. 
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3.4.3.3. Hierarchical clustering 
Given a set of items to be clustered (items can be either genes or chips/experiments), 
agglomerative hierarchical clustering (HC) recursively merges items with similar items, 
or with the result of previous merges, according to their pair-wise distance (with the 
closest item pairs being merged first) (Gould, 2005). The purpose of this method is to 
group together genes that behave in a similar fashion in a certain set of experiment. As a 
result, it produces a tree structure, referred to as dendrogram, whose nodes correspond to:  
i) The original items (these are the leaves of the tree); and  
ii) The merging of other nodes (these are the internal nodes of the tree) 
Different distance measures can give different clustering results. The most common types 
of distance measurement depend on either correlation (parametric or non-parametric) or 
Euclidean distance (parametric) measurement. Once the distance between different genes 
is computed depending on how they behave in different samples, there are various ways 
of building the hierarchy/linkage:  
Single linkage - minimum distance between points in different clusters 
Complete linkage - maximum distance 
Average linkage - mean of all distances between points in different clusters 
Centroid distance - represent each cluster by its centroid and measures distances 
between them. 
Based on the results obtained from the differential gene expression by comparing 
different samples, hierarchical clustering was performed using Euclidean distance as a 
measure of similarity/dissimilarity of genes in their expression pattern and Average 
linkage as a hierarchical amalgamation rule. 
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Figure 3.9 shows heatmaps of some selected genes based on the list of differentially 
regulated genes obtained by comparing CALM/AF10 expressing cells (pRTS-1-FLAG-
CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs)  to the controls (pRTS-1 
0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs, pRTS-1 72 hrs) (comparison 5 
in table 3.5, 477 genes). The genes in figure 3.9 have been selected because the pathways 
that they are involved in were later found to be some of the strongly deregulated cellular 
processes in this study and are relevant for subsequent discussion. It can be observed that 
the selected genes shown here are mostly down-regulated after CALM/AF10 expression. 
Genes close to each other based on the hierarchy show a similar expression pattern 
indicating that they might be co-regulated by an upstream factor or that they are 
regulating each other. 
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Figure 3.9. Hierarchical clustering of differentially regulated genes obtained by comparing 
CALM/AF10 expressing cells (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 
72 hrs)  to the controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs, pRTS-1 
72 hrs). C/A stands for cells expressing DG-75 (pRTS-1-FLAG-CALM/AF10 24hrs, pRTS-1-
FLAG-CALM/AF10 72 hrs, pRTS-1-VP16-FLAG-CALM/AF10 24hrs, and pRTS-1-VP16-FLAG-
CALM/AF10 72 hrs) and Control stands for non-induced DG-75 cells containing CALM/AF10 
constructs (pRTS-1-FLAG-CALM/AF10 0hrs and pRTS-1-VP16-FLAG-CALM/AF10 0hrs) and 
vector only controls (pRTS-1 0hrs, pRTS-1 24hrs, and pRTS-1 72hrs). These genes are involved 
in DNA repair (a) and cell cycle (b). Red squares indicate up-regulation and green squares 
show down-regulated (color scale is shown under the heatmaps). The hierarchy is shown on 
the left side of the heatmaps and gene names are given on the right side.  
3.4.3.3. Principal Component Analysis 
In Affymetrix® based microarray studies each sample is represented by one chip. Each 
chip will thus have a unique expression pattern (snapshot of the expression status of 
every gene within the cell at the time of sample preparation) if all the genes on the chip 
are simultaneously considered. This is of biological interest as the physiology of a cell at 
a given time is the result of the interplay of the expression levels of the various genes in 
the cell. The more similar two samples are biologically, the higher is the similarity in 
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their expression pattern. As a single microarray chip covers the entire human genome 
(more than 20,000 genes interrogated by more than 54,000 probesets in the HGU133plus 
2.0 chip), it is usually impractical to assess every gene independently and see how its 
expression contributes to the different expression patterns that are displayed by the 
different samples. To assess this biological variability among the different samples and 
find a statistical method that would summarize this variation has always been one of the 
key challenges in the analyses of microarray data. Towards this end, the principal 
component analysis has been used extensively in numerous microarray studies. 
The principal component analysis (PCA) is a statistical method that tries to find few 
functions (usually 3, referred to as Eigenvectors or principal components) that best 
explain the variation that is observed in a dataset by reducing the number of variables 
(gene expression levels in this case) based on how strong their correlation or co-variation 
is. This is achieved by grouping genes that vary in their expression in a similar fashion 
across different samples into one function that captures their expression pattern. The 
power of a PCA is thus dependent on how highly correlated or co-varied the genes are: 
the lower the correlation the harder it is to find a small number of principal components 
that could explain the variation observed in the data set. 
In the current study, the R implementation of PCA (pcaMethods) was used to conduct a 
principal component analysis on the 9 normalized microarrays (R version 2.8.1 (2008-12-
22), Copyright© 2008, The R Foundation for Statistical Computing). 3 principal 
components were extracted that explained cumulatively 98.42% of the variation among 
the 9 different samples (see table 3.7 for further details). Based on these 3 principal 
components (PCs), new values are calculated for the expression level of each gene (factor 
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loading). Based on the loadings, a 3D scatterplot of the samples was generated that 
showed which of the samples are more similar/different depending on the position of the 
samples in the 3D space, by giving most weight to the principal component 1 (PC1) axis, 
followed by PC2 and PC3 based on their contribution to the explanation of the variation 
(Figure 3.10). 
Table 3.7. PCA result. The second (% total variance) and the last column (Cumulative % of variance) are of particular interest in this table. 
 
PCA             Eigenvalue                  % Total variance          Cumulative Eigenvalue                Cumulative % 
1 6.163022 68.47803 6.163022 68.47803 
2 2.406050 26.73389 8.569073 95.21192 
3 0.289115 3.21239 8.858188 98.42431 
 
It can be observed (figure 3.10) that the CALM/AF10 and VP16-CALM/AF10 
expressing samples (pRTS-1-VP16-FLAG-CALM/AF10 24hrs, pRTS-1-VP16-FLAG 
CALM/AF10 72hrs, pRTS-1-FLAG-CALM/AF10 24hrs, and pRTS-1-FLAG-
CALM/AF10 72hrs) cluster together, with slight deviation for the VP16-CALM/AF10 
expressing sample at 72 hrs (pRTS-1-VP16-FLAG-CALM/AF10 72hrs). Samples with 
CALM/AF10 or VP16-CALM/AF10 expression plasmids which are not induced (pRTS-
1-VP16-FLAG-CALM/AF10 0hrs and pRTS-1-FLAG-CALM/AF10 0hrs) and the vector 
only controls (pRTS-1 0hrs, pRTS-1 24hrs, and pRTS-1 72hrs) form a cluster as well. 
This is as expected because cells that are not induced (i.e. not expressing CALM/AF10 or 
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VP16-CALM/AF10) should have a gene expression pattern which is similar to the vector 
only controls (pRTS-1 0hrs, pRTS-1 24hrs and pRTS-1 72hrs). 
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Figure 3.10. 3D scatterplot of the samples with respect to the 3 principal components. Dots 
represent samples and spikes show the position of the samples on a 2D surface of PC1 and PC2 
(PC1 and PC2 together explained 95% of the variance). Red labels (and red-shaded area) are 
all samples that were induced to express CALM/AF10 (pRTS-1-VP16-FLAG-CALM/AF10 
24hrs, pRTS-1-VP16-FLAG CALM/AF10 72, pRTS-1-FLAG-CALM/AF10 24hrs, and 
pRTS-1-FLAG-CALM/AF10 72hrs). Blue labels and shading represent non-induced 
experimental samples (pRTS-1-VP16-FLAG-CALM/AF10 0hrs and pRTS-1-FLAG-
CALM/AF10 0hrs). Green labeling and shading show vector only controls (pRTS-1 0hrs, 
pRTS-1 24hrs, and pRTS-1 72hrs). NB: shades only show sample classification and not 
necessarily clustering. 
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3.4.4. Chromosomal distribution of differentially regulated genes  
One of the interesting ways to look at microarray data is to examine the global 
transcriptional consequence by plotting the differentially expressed genes according to 
their chromosomal location. The main objective would be to look at interesting 
chromosomal locations or positions that might be significantly affected. This might be an 
indication of positional co-regulation of groups of genes. 
3.4.4.1. dChip based analysis of chromosomal distribution of differentially regulated 
genes 
The dChip software can plot the differentially regulated genes according to their location 
in the genome. The genes are assigned to their location on the chromosome and are 
indicated by red (up-regulated) or green (down-regulated) bars. The position of a bar with 
respect to the middle line indicates the direction of transcription: if the bar is above the 
middle line it indicates that the gene is transcribed from the sense strand and if it is below 
the middle line it shows that the gene is transcribed from the anti-sense strand. The genes 
on each chromosome are placed proportionally from chromosomal position 0 to the gene 
with the maximal chromosomal position in the Genome information file. The test is 
carried out at a cut point of 500 kbp of a stretch of a chromosome on either side of a 
differentially regulated gene with respect to its transcription start site. The p-values are 
calculated for all stretches containing less or equal to 20 differentially regulated genes to 
assess the significance of “gene proximity”. It is an evaluation of the “tightness” (the 
rank distance of the genes on the two ends of the stretch, in Mbp) of a stretch of n genes 
(real gene distribution) against that of n genes randomly put on the chromosome (relative 
position of genes along the chromosome if they were randomly distributed). This way, 
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gene density along a chromosome will be taken into account. For example, on 
chromosome 6, the stretch from gene 1 to 9 has a p-value 0.021799, indicating that this 
stretch of chromosome is gene rich as a p-value of 0.021799 is significant and rejects the 
hypothesis that genes are randomly distributed along a chromosome. These significant 
gene stretches are outlined in blue boxes. If a significant longer stretch contains a 
significant shorter stretch, only the longer one is reported and outlined. Since there is no 
correction for multiple hypotheses testing, the p-values here are used for drawing 
attention to specific genes. 
In the current study, the list of differentially regulated genes obtained by comparing 
pRTS-1-FLAG-CALM/AF10 expressing cells (pRTS-1-FLAG-CALM/AF10 24hrs and 
pRTS-1-FLAG-CALM/AF10 72hrs) versus controls (pRTS-1 0hrs, pRTS-1-FLAG-
CALM/AF10 0hrs, pRTS-1 24 hrs, pRTS-1 72 hrs, comparison criterion 5 in table 3.5) 
was used to generate figure 3.11. It can be observed that there are a number of significant 
cluster of differentially regulated genes, as indicated by the blue bars/boxes. Each region 
can be further investigated by examining the differentially regulated genes. For instance, 
chromosome 10 is interesting as it is: 
a. The chromosome that contains one of the fusion partners of CALM, namely AF10 
and 
b. Previous work by our group on patient microarray data that compared 10 
CALM/AF10+ AML and ALL patients to 119 cases of other leukemias (CML, 
ALL with 1;19 or 4;11, ALL with MLL rearrangement, ALL, ALL with Ph+, 
AML with MLL rearrangement, AML normal karyotype, AML normal karyotype 
FLT3+, AML with inv(16), AML with t(8;21), AML with t(15;17), AML with 
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complex karyotype; all with 10 samples each except ALL with MLL 
rearrangement (9)) and to 10 normal bone marrow samples showed that genes 
located close to the breakpoint of the t(10;11)(p12;q14)  translocation on 10p12 
(COMMD3, SPAG6, BMI and DNAJC1) were found to be at least 1.5 fold 
differentially regulated (unpublished data). To see if such an effect is also 
observable in our model, we examined chromosome 10 more closely in the next 
section. 
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Figure 3.11. Genomic distribution of differentially expressed genes (chromosomes are not 
drawn to scale) based on comparison of pRTS-1-FLAG-CALM/AF10 expressing cells (pRTS-
1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72hrs) versus controls 
(pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs, pRTS-1 72 hrs, 
comparison criterion 5 in table 3.5.).Yellow shading indicates the chromosome and non-
shaded areas within the chromosome indicate clusters of differentially regulated that are 
composed of smaller significant clusters. 
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3.4.4.2. MicroArray Chromosome Analysis Tool (MACAT) 
The MicroArray Chromosome Analysis Tool (MACAT) aims at linking the term 
differential gene expression to the chromosomal localization of genes. It is a statistical 
approach for identifying regions on the chromosomes that contain significantly 
differentially expressed regions on the chromosomes based on a regularized t-statistic 
(Toedling et al., 2004).  
Figure 3.12. MACAT analysis for chromosome 10. Y axis show level of differential regulation for 
the comparison pRTS-1-FLAG-CALM/AF10 expressing cells (pRTS-1-FLAG-CALM/AF10 24hrs 
and pRTS-1-FLAG-CALM/AF10 72hrs) versus controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 
0hrs, pRTS-1 24 hrs, pRTS-1 72 hrs, comparison criterion 5 in table 3.5). Black points show 
probesets,the red line indicates the mean fold up or down regulation of probesets of a given 
gene and grey lines indicate cut offs for differential regulation (1.5 fold in this case). Yellow 
spots on the red line indicate a gene that satisfies the cut point for differential regulation.  The 
list of probesets that significantly deregulated is given on the right-side of the plot. 
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The MACAT analysis was performed using the Bioconductor© implementation of the 
MACAT package in R (R version 2.8.1 (2008-12-22), Copyright© 2008, The R 
Foundation for Statistical Computing) (Toedling et al., 2004). The analysis revealed that 
there are some closely spaced genes on chromosome 10 that are differentially regulated. 
The yellow spots indicate genes that are statistically differentially regulated with respect 
to the calculated t-statistic. The distribution of the genes along chromosome 10 and their 
probesets are given in figure 3.12. It should be noted that there were no clusters of genes 
located close enough to each other to suggest co-regulation that could be explained by 
our current knowledge of chromatin architecture (i.e. genes within a smaller than 1 Mbp 
region). The MACAT analysis was performed for the entire genome (for all 
chromosomes) and there were no clusters of genes with very close proximity (<= 100 
kbp) that were significantly differentially regulated. 
3.4.5. Ontology Analysis (GOSurfer) 
One of the major challenges in microarray based experiments is to analyze the data in a 
way that gives biological insight into the overwhelming amount of data generated. Even 
though looking at the top up and down-regulated genes in a list of differentially regulated 
genes seems to be a plausible approach, it is known that biologically relevant gene 
expression changes might not always be so dramatic. Slight changes in the expression 
levels in a number of genes belonging to a certain biological processes might be 
biologically more relevant than a large change in a single gene. As a result, pathway and 
biological process analysis of microarray data has become one of the important analyses 
of gene expression profiling studies. Various scientific databases (predominantly Kyoto 
Encyclopedia of Genes and Genomes (KEGG) and GenMAPP) are striving to arrive at a 
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consistent and proper annotation of genes with respect to the processes that they are 
involved in, the functions that they perform, and where exactly they are found within the 
cell. 
The Gene Ontology (GO) project is a collaborative effort to address the need for 
consistent description of the function of a gene product in different databases 
(http://www.geneontology.org/GO.doc.shtml). The project began as collaboration 
between three model organism databases, FlyBase (Drosophila), the Saccharomyces 
Genome Database (SGD) and the Mouse Genome Database (MGD), in 1998. The three 
organizing principles of GO are: cellular component, biological process and molecular 
function. A gene product might be associated with or located in one or more cellular 
components; it is active in one or more biological processes, during which it performs 
one or more molecular functions.  
There are many software packages currently available that can build GO hierarchies. The 
GoSurfer package (Zhong et al., 2004) was used to analyze the microarray data in this 
study. GoSurfer uses Gene Ontology (GO) information to analyze gene sets obtained 
from genome-wide computations or microarray analyses (Zhong et al., 2004). It 
associates user defined gene lists with GO terms and visualizes such GO terms as a 
hierarchical tree. The tree output can be manipulated by various means, like setting 
heuristic thresholds or using statistical tests. Significantly important GO terms, which 
were found to be significant, can be highlighted.  
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3.4.5.1. Molecular Function 
The molecular function category describes activities such as catalysis or binding 
activities that occur at the molecular level. The GO analysis was based on the comparison 
of pRTS-FLAG-CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-
FLAG-CALM/AF10 72 hrs) to the controls pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 
0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs (comparison criterion 5 in table 3.5, 477 genes). 
The GO analysis of the microarray data revealed that binding, transcription regulator 
activity (subcategory transcriptional repressor activity) and catalytic activity were the 
three GO molecular function classes in which the differentially regulated genes were 
statistically overrepresented. Subcategories within the binding class that contained most 
of the differentially regulated genes were “damaged DNA binding”, “chromatin binding”, 
and “tubulin binding” (Figure 3.13). 
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Figure 3.13. Molecular Function. The GO molecular function is classified into 11 functional classes (list shown at the bottom of the figure). 
Functional classes that showed strong enrichment of the differentially regulated genes based on the comparison of pRTS-FLAG-CALM/AF10 
samples (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 
0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs, comparison criterion 5 in table 3.5, 477 genes) are highlighted. Dark brown and orange branches 
were found to be statistically significant for the enrichment of the genes in those sub-categories of molecular functions (boxes with different 
colors and labels), whereas grey branches are statistically not significant. 
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Figure 3.14. Biological Process. The GO molecular function is classified into 7 biological processes. Biological processes that showed strong 
enrichment of the differentially regulated genes based on the comparison of pRTS-FLAG-CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 
24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs, 
comparison criterion 5 in table 3.5, 477 genes) are highlighted. Dark brown and orange branches were found to be statistically significant for 
the enrichment of the genes in those sub-categories of biological processes (boxes with different colors and labels) whereas grey branches are 
statistically not significant.
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3.4.5.2. Biological Process 
A biological process is series of events accomplished by one or more ordered assemblies 
of molecular functions. Examples of broad biological process terms are cellular 
physiological process or signal transduction. Examples of more specific terms are 
pyrimidine metabolic process or alpha-glucoside transport. It can be difficult to 
distinguish between a biological process and a molecular function, but the general rule is 
that a process must have more than one distinct steps. A biological process is not 
equivalent to a pathway. 
Genes from several important  biological processes were were significantly 
overrepresented in the set of differentially regulated genes comparing pRTS-FLAG-
CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-
CALM/AF10 72 hrs) to the controls pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, 
pRTS-1 24 hrs and pRTS-1 72 hrs (comparison criterion 5 in table 3.5, 477 genes). The 
biological processes that showed statistically significant enrichment among the 
differentially regulated genes were: NFκB cascade, JAK-STAT cascade, DNA damage 
checkpoint, and regulation of cell proliferation (Figure 3.14). To further understand 
which genes in these pathways are affected and how this would affect the whole process, 
a pathway analysis was carried out. 
3.4.6. Pathway Analysis (KegArray) 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database for uncovering 
higher-order systemic behaviors of the cell and the organism from genomic and 
molecular information (Kanehisa and Goto, 2000). The KEGG consortium developed a 
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number of algorithms that assist the analysis of data sets (e.g. microarray, Real-time PCR 
or sequencing) by exploiting the information available in the KEGG database. KegArray, 
for instance, is a tool developed to schematically display the distribution of differentially 
regulated genes in a given pathway. 
Since our data set revealed, based on the hierarchical clustering and GO biological 
process findings, that cell cycle and DNA damage and repair are some of the significantly 
affected pathways/processes, the KegArray tool was used to investigate this in further 
detail. 
3.4.6. 1. Cell cycle 
Except for three genes (SMAD2/3, Ink 4a-d, and ATM/ATR), all the differentially 
regulated genes involved in cell cycle regulation were downregulated (Figure 3.15), 
based on comparison of pRTS-1-FLAG-CALM/AF10 samples (pRTS-1-FLAG-
CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 
0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs; comparison 
criterion 5 in table 3.5). Two of the six origin recognition complex (ORC) genes and four 
of the six mini-chromosome maintenance (MCM) genes were down-regulated. How the 
down-regulated and up-regulated genes interact and how CALM/AF10 might affect the 
cell cycle will be described in more detail in the discussion section.  
3.4.6. 2. DNA damage checkpoint and DNA repair 
The list of differentially regulated genes includes a number of genes that have been 
implicated in various types of cancer including BRCA1, DDB2, CHEK1 and RAD5. All 
four genes were down-regulated (comparison criterion 5 in table 3.5). Most of the other 
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genes in this category were also down regulated, indicating that DNA damage checkpoint 
is one of the important pathways affected early after the expression of CALM/AF10. 
Figure 3.16 shows the nucleotide excision repair process and some of the genes (DDB2, 
PCNA, and LIG1) that were found to be differentially regulated in our comparison stated 
above. 
Results 
 
  112 
 
 
 
 
 
 
 
 
Figure 3.15.  Cell cycle based on KEGG. Green boxes are down-regulated genes and red are up-regulated. Grey indicate genes that are not 
differentially regulated (based on comparison of pRTS-1-FLAG-CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-
CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs (comparison criterion 5 in 
table 3.5)). 
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3.16. Nucleotide excision repair based on KEGG. A number of genes involved in Nucleotide 
excision repair (part of the DNA damage repair) including LIG1, DDB2 and PCNA were 
down0regulated in the comparison of  the  pRTS-1-FLAG-CALM/AF10 samples (pRTS-1-FLAG-
CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs) with the controls (pRTS-1 0hrs, 
pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs) (comparison criterion 5 in 
table 3.5). 
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3.4.7. Comparison with patient data (Gene Set Enrichment Analysis, GSEA) 
The Gene Set Enrichment Analysis  is another powerful pathway/biological process 
orientated analytical method that derives its power by focusing on gene sets, which are 
defined as groups of genes that share common biological function, chromosomal 
location, or regulation (Subramanian et al., 2005). Notably, where single-gene analysis 
finds little similarity between two independent studies (like patient data and cell line 
data), GSEA might reveal many biological pathways which are affected in both studies. 
A false discovery rate (FDR) adjustment can be made for multiple testing by setting a 
certain threshold. 
In the current study, it was attempted to employ the power of this tool to find pathways 
that might be affected by CALM/AF10 both in the patient data set and the cell line data 
set of this study.  
The patient data set used here is derived from microarray based (Affymetrix platform) 
expression profiling study using mononuclear cells from bone marrow aspirates collected 
from patients with CALM/AF10 and other types of leukemia. 10 CALM/AF10+ AML 
and ALL patients were compared to 119 patients with various types of leukemia (CML, 
ALL with 1;19 or 4;11, ALL with MLL rearrangement, ALL, ALL with Ph+, AML with 
MLL rearrangement, AML normal karyotype, AML normal karyotype FLT3+, AML 
with inv(16), AML with t(8;21), AML with t(15;17), AML with complex karyotype; all 
with 10 samples each except the group of ALL with MLL rearrangements (9)). 10 normal 
bone marrow samples were also included in the study. The purpose of the study was to 
identify genes which are up and down-regulated in CALM/AF10 patients as compared to 
other classes of leukemia and normal bone marrow controls. As the nature of the samples 
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and the comparison method in the patient data set and the cell line data set are not suited 
for direct comparison, the aim of GSEA is to assess if there are some pathways affected 
by CALM/AF10 both in the cell line data (immediate target genes) and in the patient data 
(differentially regulated genes compared to other leukemia subtypes).  
The list of genes that were found to be differentially regulated in the cell line data 
(comparison of  pRTS-1-FLAG-CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 
24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-
FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs) were used as a reference 
gene set for the GSEA. The reference gene set is the set of genes that was used to build 
the enrichment analysis when comparing the CALM/AF10 patient data to all the other 
classes of leukemia (a t-test was used as a metric for finding and ranking differentially 
regulated genes when comparing CALM/AF10 patient microarray data to other patient 
classes). In the process, for every match in the reference gene list with the comparison of 
patient samples for differentially regulated genes in CALM/AF10 patients is encountered, 
a positive score is entered, named as Enrichment Score (ES). The ES increase steeply if 
more genes in the reference list are matching with the most differentially regulated genes 
in the patient microarray data comparisons. The GSEA was run with 1000 iterations 
based on the reference gene set from the cell line data, there were no statistically enriched 
genes in the patient comparison. This implies that the set of genes that were differentially 
regulated in the cell line data are different from the set of differentially regulated genes in 
the patient data.  
To assess if biological processes or molecular functions that were enriched in the cell line 
data from the GO and KEGG analysis would also be implicated in the patient data, the 
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GSEA was carried out on the patient data using GO biological process and molecular 
function as a reference gene set.  Using this approach, we discovered that the pathway 
"DNA repair" was significantly enriched both in the cell line data and the patient data, 
even though the list of differentially regulated genes in the two different settings (cell line 
data and patient data) did not overlap. Figure 3.17 summarizes the result of the GSEA of 
the patient and cell line data. The involvement of DNA repair in both data sets indicates 
that a compromised DNA repair pathway with its ensuing genomic instability might be 
one of the oncogenic mechanisms of CALM/AF10-mediated leukemogenesis. 
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Figure 3.17. GSEA based on cell line and patient data described above (section 3.4.7.).(a) 
Enrichment of genes involved in DNA repair in the list of differentially regulated genes 
obtained by comapring pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs 
to the controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 
hrs) (b) 10 CALM/AF10+ AML and ALL patients were compared to CML, ALL with 1;19 or 4;11, 
ALL with MLL rearrangement, ALL, ALL with Ph+, AML with MLL rearrangement, AML normal 
karyotype, AML normal karyotype FLT3+, AML with inv(16), AML with t(8;21), AML with 
t(15;17), AML with complex karyotype, and Normal bone marrow samples; all with 10 samples 
each except ALL with MLL rearrangement (9)). After evaluation of differentially regulated 
genes based on a t-statistic, the genes were arranged in ascending order. Based on this ordered 
list, the GSEA gives a positive score (y axis) for every gene encountered that belongs to the DNA 
repair process (green curve). Each hit is represented by a vertical bar on the x axis. The 
stronger the enrichment of genes belonging to DNA repair, the higher will be the density of 
bars on the left most side of the x axis. 
 
3.5. Verification of Potential Target Genes by Real Time PCR (Taqman® 
Low Density Array) 
The differential expression of genes found in microarray study is often validated using 
real-time reverse transcription PCR (RT-PCR) assays.  
Real-time reverse-transcriptase (RT) PCR is able to quantify the amount of the template 
very specifically, sensitively and reproducibly. Real-time PCR monitors the fluorescence 
(a)                     (b) 
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emitted during the reaction as an indicator of amplicon production during each PCR cycle 
(i.e. in real time) as opposed to endpoint detection (Dorak, 2006). In comparison to 
conventional RT-PCR, real-time PCR also offers a much wider dynamic range of up to 
107-fold (compared to 1000-fold in conventional RT-PCR). The dynamic range of any 
assay determines how much the target concentration can vary and still be quantified. A 
wide dynamic range ensures that a wide range of ratios of target and normalizer can be 
assayed with equal sensitivity and specificity (Dorak, 2006). It follows that the broader 
the dynamic range is, the more accurate the quantitation is. In real-time RT-PCR assays, 
expression is normalized to a control or housekeeping gene.  
An important parameter in real-time PCR analysis is the Ct value, a threshold cycle that 
should be placed above any baseline activity and within the exponential phase (which 
looks linear in the log transformation) (Dorak, 2006) of PCR amplification. The Ct is thus 
the cycle at which the PCR reaction has reach mid-phase of the exponential increase 
phase, and it serves as a reference cycle for subsequent analysis and comparison between 
different samples in a given experiment. 
TaqMan® Low-Density Arrays based real-time PCR is a medium-throughput method 
using microfluidics to simultaneously assay the expression of many genes (Lynne V. 
Abruzzo et al., 2005). For the details of experimental setup, please see Materials and 
methods section on the Taqman Low Density Array. 
We selected ninety four genes from the list of significantly differentially regulated genes 
(comparing pRTS-1-FLAG-CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 24hrs 
and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-FLAG-
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CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs)) for validation of their expression 
changes by real-time RT-PCR on the LDA (the genes are listed in Appendix A7). Two 
house-keeping genes (β-actin and GAPDH) were included in the validation real-time 
PCR experiment. The differentially regulated genes were selected based on the overall 
assessment of the analysis of the microarray data and their potential and known 
biological significance in leukemogenesis and hematopoietic development.  
The cDNA that was used for the LDA real-time PCR was produced from the same total 
RNA that was used as a starting material for the microarray study. All samples from all 
time points (non-induced, 24 hrs after induction, and 72 hrs after induction) were 
included in the real-time PCR study. The cDNA synthesis was performed 3 times from 
the RNA that was used as a starting material for the microarray study and each synthesis 
product was used as a replicate for the LDA experiment. Samples were loaded randomly 
on an LDA (no systematic order) to avoid bias. The Materials and Methods section on the 
Taqman Low Density Array describes the LDA protocol and machine setup. 
Once the data were acquired successfully, the individual Ct values of the assayed genes 
(Figure 3.18) were normalized against the geometric mean of the Ct value of the two 
internal control genes (β-actin and GAPDH). The raw amplification kinetics of the 94 
genes on the TaqMan system is shown in figure 3.18. As can be seen in this figure most 
of the genes had a Ct value in the range of 25 to 37 (80.1% of the genes). Very few genes 
(3.7%) showed a relatively narrow Ct value range (high expression level), ranging from 
20 to 22. After completion of the normalization, the data points were exported to a 
spreadsheet for further statistical analysis. 
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The fold expression change for the 94 genes was calculated using the same approach used 
for the microarray data (Table 3.5), the only difference being in the LDA data that the 
mean expression value (and standard deviation) for each gene in a given sample was 
calculated based on the 3 replicates per sample that were included in the LDA 
experiment. 
The list of genes and their fold expression for the comparison pRTS-1-FLAG-
CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-
CALM/AF10 72 hrs) to the controls pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, 
pRTS-1 24 hrs and pRTS-1 72 hrs) in both the real-time PCR analysis and in the 
microarray experiments is given in Appendix A7.  
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Figure 3.18. Raw real-time PCR data of the 94 genes and all samples in the experiment.  Y axis 
is the magnitude of the signal generated by the given set of PCR condition and is calculated by 
taking the difference between Rn+ (the reaction containing all components, including the 
template) and Rn- (the reaction without the template) (Rn is the fluorescence emission 
intensity of the reporter dye divided by the fluorescence emission intensity of the passive 
reference dye). Red horizontal line is the Ct value, which is calculated automatically by the 
software). The X axis represents the cycle number. Different colors indicate readings for 
different genes. 80.1% of the assayed genes had Ct values ranging from 25 to 37. 
3.5.1. Comparison between array and LDA data 
The fold expression changes obtained from the LDA real-time PCR analysis were 
compared to the fold expression changes observed in the microarray data, based on the 
comparison pRTS-1-FLAG-CALM/AF10 samples (pRTS-1-FLAG-CALM/AF10 24hrs 
and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-FLAG-
CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs). A Pearson’s correlation analysis 
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revealed that there was a strong correlation between the two data sets (table 3.8 and 
figure 3.19).  If one considers the absolute value of the fold expression change as shown 
in figure 3.19., 78% of the genes in the validation list were consistent in the direction of 
their regulation (most genes up-regulated in the microarray data set upon CALM/AF10 
expression were also found to be up-regulated in the LDA analysis; and the same was 
true for the down-regulated genes). Some gene that did not show matching direction of 
deregulation include IFI27, USP18, TLX2, RAB8B. 
The difference in the magnitude of differential regulation between the real-time PCR data 
and the microarray data was also evaluated for the pRTS-1-FLAG-CALM/AF10 24hrs 
and pRTS-1-FLAG-CALM/AF10 72 hrs) to the controls (pRTS-1 0hrs, pRTS-1-FLAG-
CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs) comparison. It was observed that 
there is an overall higher magnitude of differential regulation (on average 2.5 fold higher) 
in the real time PCR data as compared to the microarray data. This difference in the 
magnitude of fold expression can be accounted for by the greater dynamic range of real-
time PCR as compared to the Affymetrix microarray. 
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Table 3.8. Pearson’s correlation of Affymetrix data and real-time PCR LDA data (In bold, significant values (except diagonal) at the level of significance alpha=0.050 (two-tailed test)) 
Figure 3.19. Correlation of microarray data and LDA real-time PCR data. The X axis represents 
the fold difference in regulation of the selected genes in the real-time PCR setting for the 
comparison of pRTS-1-FLAG-CALM/AF10 24hrs and pRTS-1-FLAG-CALM/AF10 72 hrs to the 
controls (pRTS-1 0hrs, pRTS-1-FLAG-CALM/AF10 0hrs, pRTS-1 24 hrs and pRTS-1 72 hrs) 
(log2 scale, green error bars indicating standard deviation for the fold regulation based on the 
technical replicates). Y axis indicates fold regulation for microarray data for the same 
comparison criterion, purple error bars indicating 95% confidence intervals. 
 LDA Affymetrix 
LDA 1.000 0.780 
Affymetrix 0.780 1.000 
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IV. Discussion  
 It was the aim of this work to identify the early or immediate targets of CALM/AF10. To 
achieve this CALM/AF10 was expressed from the inducible mammalian expression 
vector pRTS-1 in the cell line DG-75, and the changes in the expression levels of 
~20,000 genes was measured by expression profiling on the Affymetrix platform. The 
conditional expression of a gene of interest gives control over the time and dose of 
expression of the gene to be induced. As clean and appealing as a conditional expression 
system is there are some inherent limitations which have to be considered. The choice of 
the cell line plays a critical role in an experiment like ours, as the appropriateness of the 
cell line for the problem to be addressed and the technical feasibility of using the cell line 
have to be reconciled. For instance, out of the different cell lines screened for this work, 
the DG-75 cell line performed best with regard to inducibility and absence of leaky 
expression of CALM/AF10 prior to induction. DG-75 is a human memory pro B cell line 
(Burkitt's lymphoma cell line) and is certainly appropriate for this work as it is a 
hematopoietic. However, this cell line is a partially differentiated cell line and has 
accumulated certain epigenetic modifications that might mask the effect of CALM/AF10 
on certain target genes. Despite the afro mentioned limitations and other intrinsic 
setbacks, gene expression profiling using Affymetrix® microarray of the different 
samples collected at different time points after induction of expression of CALM/AF10 
provided us with a good overview of the transcriptional consequence of CALM/AF10 
both at the gene and pathway level. 
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It is quite obvious that the number of differentially regulated genes in this is study is very 
large and these results cannot be discussed in all the details. Therefore, we chose to focus 
our discussion on the genes and pathways that appeared most relevant to us and that were 
validated in our real time PCR experiments (see results section and figure 4.1). 
Figure 4.1. Some selected genes differentially regulated after CALM/AF10 expression in the 
DG-75 cell line. 
4.1. Some genes implicated in cancer are immediate targets of 
CALM/AF10 
BRCA1 
Several known oncogenes and tumor suppressor genes were found to be differentially 
regulated after CALM/AF10 expression. BRCA1 (breast cancer 1, early onset), is one of 
these genes. BRCA1 was down-regulated in DG-75 cells expressing CALM/AF10. 
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BRCA1 encodes a nuclear phosphoprotein that plays a role in maintaining genomic 
stability and acts as a tumor suppressor. It was initially identified as the gene mutated in 
families with early onset breast cancer (Futreal et al., 1994, Chen et al., 1996). The 
BRCA1 protein associates with other tumor suppressor proteins, DNA damage sensors, 
and signal transducers to form a large multi-subunit protein complex known as BASC for 
BRCA1-associated genome surveillance complex (Wang et al., 2000). BRCA1 muations 
are responsible for approximately 40% of familial breast cancers and for more than 80% 
of familial breast and ovarian cancers and it has recently been implicated as a  predictive 
marker of poorer overall survival in sporadic ovarian cancer (Weberpals et al., 2009). It 
is tempting to speculate that the down-regulation of BRCA1 might play a role in the early 
stages of CALM/AF10-mediated oncogenesis by facilitating the accumulation of 
additional mutations which are necessary for the development of the full leukemic 
phenotype. 
RARA 
RARA (retinoic acid receptor, alpha) was another gene that was found to be up-regulated 
in this experiment. Translocations which involve the RARA  gene are a cardinal feature of 
acute promyelocytic leukemia (APL) (Goddard et al., 1992), the most common of these 
translocations is the  t(15;17)(q21;q22), which fuses the RARA gene with the PML gene 
(Vitoux et al., 2007). The result of the different RARA fusions is a loss of wild type RARA 
function. Therefore, the significance of a higher expression of RARA in the context of 
leukemogenesis is not clear. It has been shown in gene profiling of colonic serrated 
adenomas by using oligonucleotide microarray that RARA is one of the three significantly 
up-regulated genes (Kim et al., 2008). In contrast, it has recently been reported that 
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diminished RARA expression contributes to leukemogenesis in acute myeloid leukemia 
cell lines, though the regulation of expression of this gene was very complex and varies at 
different stages of the disease (Glasow et al., 2008). 
FOXP1 
Forkhead box transcription factors play important roles in the regulation of tissue- and 
cell type-specific gene transcription during both development and adulthood. One of 
these genes, FOXP1 (forkhead box P1), was found to be one of the immediate targets of 
CALM/AF10. The up-regulation of FOXP1 has also been associated with invasive breast 
carcinomas (Bates et al., 2008). It has also been reported that deregulation of FOXP1 
expression (over-expression) plays an important role in lymphoma development (Goatly 
et al., 2008). Similarly, up-regulated mRNA expression of the FOXP1 forkhead 
transcription factor in response to normal B-cell activation and high expression in a poor 
prognosis subtype of diffuse large B-cell lymphoma (Banham et al., 2005) is an 
indication that this gene is one of the more interesting targets of CALM/AF10. 
PBXIP1 
PBXIP1 (pre-B-cell leukemia homeobox 1 interacting protein 1), also known as HPIP 
(hematopoietic PBX-interacting protein), was up-regulated upon the expression of 
CALM/AF10. PBX1 is a transcription factor originally discovered as the chromosome 1 
participant in the translocation t(1;19) which results in the E2A/PBX1 fusion protein, 
seen frequently in pediatric acute lymphoblastic leukemia (Kamps et al., 1990). HPIP 
interacts with PBX1, which is a homeodomain protein that functions in complexes with 
other homeodomain-containing proteins to regulate gene expression during 
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developmental and/or differentiation processes (Abramovich et al., 2000). Abramovich et 
al. (2000) showed that HPIP inhibits the ability of PBX1-HOX heterodimers to bind to 
target sequences and suggested that HPIP is a new regulator of PBX1 function 
(Abramovich et al., 2002). 
4.2. The MLL gene family 
MLL (myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)) is a 
frequent target for recurrent translocations in acute leukemias that may be characterized 
as acute myeloid leukemia, acute lymphoblastic leukemia (ALL), or mixed lineage 
(biphenotypic) leukemia (MLL) (Krivtsov and Armstrong, 2007). Leukemias with 
translocations involving MLL possess unique clinical and biologic characteristics and are 
often associated with poor prognosis (Krivtsov and Armstrong, 2007). MLL 
rearrangements are found in more than 70% of infant leukemias, where the 
immunophenotype is more consistent with ALL or AML-M6, but are less frequent in 
leukemias from older children. MLL translocations are also found in approximately 10% 
of AMLs in adults (Matthew et al., 2008), as well as in therapy-related leukemias, that 
develop in patients previously treated with chemotherapeutic agents (mainly 
topoisomerase II inhhibitors) for other malignancies (Millot et al., 2005). A key feature 
of MLL fusion proteins is their high efficiency in transforming hematopoietic cells 
(Krivtsov and Armstrong, 2007). The MLL gene encodes a DNA-binding protein that 
methylates histone H3 lys4 (H3K4) and positively regulates expression of target genes, 
notably multiple HOX genes (Ansari et al., 2008). MLL-like genes are part of the 
trithorax-polycomb system which is crucial in maintaining gene expression patterns 
established during developmental processes (epigenetic memory).  
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In the current experiment, two members of the MLL gene family (MLL3 and MLL5) 
were found to be up-regulated. MLL3 encodes a nuclear protein and has not yet been 
associated with malignancies while MLL5 has been shown to upregulated in certain 
subsets of myeloid leukemias (Emerling et al., 2002). Though the role of  MLL5 
overexpression in cell cycle regulation has been reported (Deng et al., 2004, Cheng et al., 
2008), additional functional studies are required to assess the role of MLL3 or MLL5 up-
regulation in CALM/AF10-mediated leukemogenesis. 
4.3. Important Signalling Pathways are Affected by CALM/AF10 
4.3.1. Notch signaling 
Notch signaling is one of the most important pathways in the cell and controls 
differentiation and proliferation in various cell types and is associated with several 
diseases (Karlsson et al., 2008). The Notch family of evolutionarily conserved proteins 
regulates a broad spectrum of cell-fate decisions and differentiation processes during fetal 
and post-natal development. The best characterized role of Notch signaling during 
mammalian hematopoiesis and lymphopoiesis is the essential function of the Notch1 
receptor in T-cell lineage commitment. More recent studies have addressed the roles of 
other Notch receptors and ligands, as well as their downstream targets, revealing 
additional novel functions of Notch signaling in intra-thymic T-cell development, B-cell 
development and peripheral T-cell function. It has been shown that more than 50% of 
human T-ALLs, including tumors from all major molecular oncogenic subtypes, have 
activating mutations that involve the extracellular heterodimerization domain and/or the 
C-terminal PEST domain of NOTCH1 (Weng et al., 2004). Importantly, the 
CALM/AF10 fusion gene is most frequent fusion gene in T-ALL with T-cell receptor γ/δ 
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rearrangements, being present in 20% of the cases. Aberrant Notch signaling has also 
been found in other neoplastic and non-neoplastic conditions like osteoarthritis (Karlsson 
et al., 2008), melanoma (Bedogni et al., 2008) and mesothelioma (Graziani et al., 2008).  
In this study, it was observed that one of the positive regulators of Notch signaling, 
MAML3 (mastermind-like 3 (Drosophila)), is significantly up-regulated. Mastermind 
(Mam) is one of the evolutionarily conserved elements of the Notch signaling pathway. 
The Drosophila gene mastermind is an important positive regulator of the pathway (Lin 
et al., 2002). Lin et al. (2002) discussed that both MAML2 and MAML3 stabilize and are 
part of the DNA-binding complex containing RBP-J/CBF-1 and the Notch intracellular 
domain, which assembles at the promoter of Notch target genes. It is very likely that 
MAML3-mediated Notch activation plays a role in CALM/AF10-mediated 
leukemogenesis since all CALM/AF10 positive patients (both AML and ALL) have a 
TCR γ/δ rearrangement. In addition, we observed that NOTCH1 itself is up-regulated in 
CALM/AF10 patients using microarray analysis (unpublished data). 
4.4. DNA damage check-point and DNA repair 
 
Interestingly, several genes involved in DNA damage sensing, DNA damage check-point 
and DNA repair were found deregulated after expression of CALM/AF10. Most of these 
genes were found to be down-regulated. 
One of the very interesting genes in the DNA damage check-point pathway is ATM 
(ataxia telangiectasia mutated), a gene that belongs to the PI3/PI4-kinase family and 
plays an important role in cell cycle control after DNA damage. This gene was found to 
be significantly up-regulated. Mutations in the ATM gene lead to Ataxia teleangiectasia, a 
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recessive autosomal disease characterized by cerebellar ataxia (progressive difficulty in 
walking and other movements), teleangiectasia (dilatation of small arteries) and 
immunodeficiency. It is also characterized by increasing sensitivity to radiations and by a 
high probability of developing leukemias or other tumours. 
 ATM functions as a regulator of a wide variety of downstream proteins, including tumor 
suppressor proteins like  TP53 and BRCA1, the checkpoint kinase CHK2, the checkpoint 
proteins RAD17 and RAD9, and the DNA repair protein NBS1 (Antoccia et al., 2008). 
ATM is crucial for the maintenance of chromosomal integrity. The absence of ATM 
kinase activity may lead to the rapid accumulation of irreversible chromosome damage 
(White et al., 2008). Mutations and deletions of ATM are frequently found in chronic 
lymphocytic leukema (CLL) (Wei et al., 2008) and childhood malignancies (Fabienne et 
al., 2008). Some findings also suggest that overexpression of ATM may be one of the 
early events in the carcinogenesis of oral squamous cell carcinoma (He et al., 2008). It 
has been reported that there is an increased need for ATM signaling for double strand 
break and repair as the heterochromatic component of a genome expands (Goodarzi et 
al., 2008). Choo and co-workers showed that ATM can signal to cyclin D1, a key 
molecule for transition between the G1 and S phases of the cell-cycle with pivotal roles 
in the development of several human cancers, may be required for maintenance of 
genomic integrity achieved by rapid arrest of the cell-cycle and that disruption of this 
crosstalk may increase susceptibility to cancer (Choo et al., 2009).  
Down-regulation of DDB2 (damage-specific DNA binding protein 2), a gene involved in 
cellular response to DNA damage with a direct DNA binding activity (Kulaksiz et al., 
2005), is also interesting as it further signifies the impact that CALM/AF10 might have in 
Discussion 
 
132 
 
DNA damage and repair. Interestingly, BRCA1 upregulates DDB2, with some evidence 
of P53 involvement in its regulation (El-Deiry, 2002), via interactions with the RAD51 
protein family. Interestingly, RAD51 (RAD51 homolog (RecA homolog, E. coli) (S. 
cerevisiae)) was found to be down-regulated in the current data. The interaction between 
RAD51 and BRCA1/BRCA2 was found to be important for the cellular response to DNA 
damage results indicate that alterations in RAD51 activity may contribute to the 
disturbances of DNA repair involving RAD51 and/or BRCA2 penetration and thus 
enhance the risk of breast cancer development (Maria et al., 2008). The association of 
RAD51 and the BRCAs has been credited to CHEK1 (another down-regulated gene in 
this study) and CHEK2 (Bahassi et al., 2008). 
Up-regulation of ATM and differential regulation of various genes involved in genomic 
stability and DNA damage repair in the current study indicate that CALM/AF10 
expression might induces genomic instability and thereby affecting DNA break and 
repair pathways which in turn might lead to cell cycle arrest. 
4.5. Cell cycle is one of the most dramatically affected pathways by 
CALM/AF10  
The connection between cell cycle control and cancer is quite obvious. The cell cycle 
machinery controls cell proliferation, and cancer is a disease of inappropriate cell 
proliferation (Collins et al., 1997). Fundamentally, all cancers permit the existence of too 
many cells. However, this excess number of cells is linked in a vicious cycle with a 
reduction in sensitivity to signals that normally tell a cell to adhere, differentiate, or die 
(Collins et al., 1997). At least two types of cell cycle control mechanisms are recognized: 
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a cascade of protein phosphorylations (involving a highly regulated kinase family) that 
are important for the progression from one stage of the cell cycle to the next, and a set of 
checkpoints that monitor completion of critical events and delay progression to the next 
stage if necessary (Collins et al., 1997).  
In this study, cell cycle was found to be one of the most dramatically affected pathways 
by CALM/AF10 which may be as a result of the significant impact of the fusion gene on 
DNA damage checkpoint genes (ATM being the checkpoint that mediates DNA damage 
checkpoint and cell cycle as discussed in the previous section). As can be noted from the 
pathway analysis (see results section on Pathway analysis sub-section Cell cycle), a 
significant proportion of the genes in cell cycle (approx. 50%) are deregulated.  
Another entry point into the cell cycle from other pathways is via SMAD2/3, which 
mediate the link between TGFβ signaling and cell cycle, playing a role in cellular 
proliferation, apoptosis, actin cytoskeleton regulation, cell motility, transcription, and Ras 
or insulin signaling (Brown et al., 2008). The SMAD genes SMAD2 and SMAD3 were 
significantly up-regulated in the current study. Aberrant expression of SMAD2 plays a 
role in hepatocellular carcinoma (Wu et al., 2007) and its up-regulation has been 
associated with Glioma (Bruna et al., 2007). It has also been reported that breast cancer 
patients with high expression of SMAD2 tended to have a better prognosis (Liapis et al., 
2007). 
The combined impact of DNA damage checkpoint and TGFβ signaling via ATM/ATR and 
SMAD2/3, respectively, seems to indirectly lead to cell cycle arrest as most of the critical 
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positive regulators of cell cycle are down-regulated in CALM/AF10 expressing DG-75 
cells.  
4.6. Genes close to the breakpoint of either AF10 or CALM are not 
immediate targets of CALM/AF10 
In a microarray-based comparison of CALM-AF10+ T-ALL to CALM-AF10- T-ALL, it 
was reported that the genes located close to AF10 breakpoint of t(10;11)(p13;q14-21) 
(DNAJC1, COMMD3, BMI1 and SPAG6) were found to be significantly up-regulated 
(Dik et al., 2005). In our CALM/AF10 patient microarray data set (section 3.4.7.), we 
were able to confirm that these genes were up-regulated (unpublished data). Interestingly, 
these genes were also found to be up-regulated in a CALM/AF10 mouse bone marrow 
transplantation model (except Spag6) despite the fact that these mice do not have the 
t(10;11)(p13;q14-21) translocation (unpublished data), implying that the up-regulation of 
these genes might be due to the direct/indirect impact of the expression of CALM/AF10 
and not as a consequence of the translocation event.   
We analyzed the expression levels of these genes (DNAJC1, COMMD3, BMI1 and 
SPAG6) in the current data set. None of these genes was found to be statistically 
significantly deregulated, indicating that they might be intermediate-late targets of 
CALM/AF10 or that strong repressive chromatin modifications are present at the these 
genes in the DG75 cell line. 
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Figure 4.2. Location of AF10 and proximal genes that were analyzed (± 500 kbp)  
4.7. Genomic instability and DNA repair might be the oncogenic pathway 
of CALM/AF10 as revealed by comparative pathway analysis of patient 
and cell line data 
It has been widely reported that genomic instability is one of the key features of 
malignancies. For instance, cases of ETP (Early T-cell Precursors)-ALL showed 
increased genomic instability, in terms of number and size of gene lesions, compared 
with those with typical T-ALL (Coustan-Smith et al., 2009). Similar results were also 
reported in proB acute lymphoblastic leukemia (Bumbea et al., 2007). The possible 
involvment of DNA damage and aberrant repair associated with internal tandem 
duplication of FLT3 (FLT3/ITD) for poor prognosis in AML (Sallmyr et al., 2008) 
indicates that genomic instability may play a pivotal role in disease progression of AML. 
The role of genomic instability and the probable causes and consequences has recently 
been reviewed (Annahita et al., 2008). Annahita and co-workers stated that disease 
progression in myeloid malignancies results from the accumulation of “mutations” in 
genes that control cellular growth and differentiation but also pointed out that the 
mechanism(s) by which these cells acquire genetic alterations or genomic instability is 
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less well understood. In reference to DNA-microarray and real-time PCR based 
expression profiling studies, a recent review also indicated that deviant gene expression 
patterns in acute myeloid leukemias should be assessed on the background of gene 
expression levels of housekeeping functions, particular differentiation stages and 
epiphenomena due to genomic instability (Oyan et al., 2007).  
Using the Gene Set Enrichment Analysis (GSEA) we could clearly show that DNA repair 
and genomic stability related pathways are significantly affected in both the 
CALM/AF10 patients’ microarray data and in the microarray data of the DG-75 cell line 
after CALM/AF10 expression. It was also observed that the genomic stability and DNA 
repair genes that are differentially regulated in the two different settings were not the 
same, indicating that early targets (cell line data) might be different from those found in 
patients. This might be explained by the difference in the nature of the samples in that 
what is observed in the cell line we see the immediate impact of CALM/AF10 in a very 
controlled setting while in the CALM/AF10 positive patient samples the microarray 
study would detect late or terminal targets. It should also be noted that in the patient 
microarray study, the samples are compared with other types of leukemia and normal 
bone marrow, which might not be the ideal controls. Despite the huge differences in the 
systems used (controlled cell line system versus "messy" patient samples) and the 
different comparisons made (induced versus uninduced, and CALM/AF10-posistive 
versus other leukemia) , it was still observed that CALM/AF10 affects genomic stability. 
This indicates that alterations of genomic stability might be one of the very important 
pathways in CALM/AF10 mediated leukemogenesis. 
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V. Summary 
The t(10;11)(p12;q14) is a recurring chromosomal translocation that is found in acute 
myeloid and acute lymphoblastic leukemia as well as in malignant lymphoma.  This 
translocation results in the fusion of AF10, encoding a putative zinc finger transcription 
factor containing an N-terminal LAP/PHD zinc finger motif, a nuclear localization signal, 
an AT-hook domain, and a leucine zipper and with the CALM gene (Clathrin assembly 
protein lymphoid myeloid leukemia gene) that encodes a clathrin assembly protein. In the 
monocytic cell line U937 both the CALM/AF10 and the AF10/CALM fusion mRNAs 
can be identified.  The CALM/AF10 fusion mRNA codes for the CALM/AF10 fusion 
protein which contains almost the complete CALM protein fused in frame to about 90% 
of the AF10 protein without the N terminal plant homeo domain (PHD) domain. 
CALM/AF10 is highly leukemogenic with its expression in primary bone marrow cells 
leading to the development of an aggressive acute leukemia with a short latency of 10 
weeks in a murine bone marrow transplant model. We set out to identify immediate target 
genes of CALM/AF10. The fusion gene was cloned into pRTS-1, an episomally 
replicating tetracycline/doxycycline inducible (tet-on) expression vector. The construct 
was stably transfected into the Burkitt’s lymphoma B cell line DG75. The expression of 
CALM/AF10 after induction was confirmed by RT-PCR. Gene expression profiling 
experiments were conducted using the Affymetrix® Human Genome U133 Plus 2.0 
Array analyzing non-induced and induced (24 and 72 hours after induction) samples. As 
controls, DG75 cells transfected with the pRTS-1 vector without the CALM/AF10 fusion 
gene were used. The results were analyzed using the R statistical package and dChip 
(DNA Chip Analyzer) software. The expression of 1237 genes was found to be changed 
at least 2 fold 24 hours after the induction of CALM/AF10. 594 (48%) genes were 
downregulated, while 643 (52%) were upregulated. Downregulated genes included genes 
involved in DNA repair (DDB2, TOP2A, BRCA1), cell cycle check point control 
(CCNE2, CHEK1, CDC2), and chromosome maintenance (MCM3, MCM7, MCM10). 
Upregulated genes included signal transduction molecules like RAB8B (a member of the 
RAS oncogene family) and STAT family members (STAT1 and STAT2), chromatin 
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remodeling factors like BAZ2A (bromodomain adjacent to zinc finger domain, 2A), and 
MAML3 (master mind like 3), a positive regulator of Notch signaling. A pathway analysis 
using KegArray showed an enrichment of differentially regulated genes in processes like 
"cell cycle regulation" and "DNA replication and repair". Interestingly, no significant 
upregulation of Hox genes was observed, as was previously reported in a study of 
CALM/AF10 positive patient samples (Dik et al., 2005). The changes in the expression 
levels of some selected genes were confirmed using a Taqman® Low Density Array 
(LDA). This analysis showed a statistically significant correlation (r = 0.78, p = 0.001) 
between the real time PCR results and the expression levels obtained from the Affymetrix 
arrays. A gene set enrichment analysis, comparing the data obtained after inducible 
expression of CALM/AF10 in DG75 cells and data obtained from gene expression 
profiling in CALM/AF10-positive patient samples, showed a significant deregulation of 
genes involved in DNA repair and genomic stability both in the differentially regulated 
genes in the cell line experiments and in the patient data. Our results demonstrate that the 
expression of the leukemogenic CALM/AF10 fusion protein leads to a severe 
deregulation of critical cellular processes, and we could identify candidate genes as direct 
target of the CALM/AF10 fusion protein. 
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Zusammenfassung 
 
Die t(10;11)(p12;q14) ist eine wiederkehrende chromosomale Translokation, die man bei der akuten 
myeloischen und akuten lymphoblastischen Leukämie (AML/ALL) und auch bei malignen Lymphomen 
findet. Diese Translokation führt zu einer eine Fusion des AF10-Gens, mit dem CALM Gen. AF10 kodiert 
einen putativen Zinkfinger-Transkriptionsfaktor, welcher ein N-terminales LAP/PHD Zink-Fingermotiv, 
ein nukleäres Lokalisationssignal, ein AT-Hook und ein Leucinzipper enthält. CALM hingegen kodiert das 
Clathrin Assembly Lymphoid Myeloid Leukemia Protein und spielt bei der rezeptorvermittelten Endozytose 
eine wichtige Rolle. In der monozytischen Zelllinie U937 konnten die mRNAs, die für CALM/AF10- und  
AF10/CALM-Fusionsproteine kodieren, identifiziert werden. Die CALM/AF10 mRNA beinhaltet fast das 
komplette CALM-Gen, an das fast 90% des offenen Leserahmens des AF10-Gens anschließen. Lediglich 
die N-terminale PHD-Domäne des AF10-Gens fehlt in dieser Fusions-mRNA. 
Die Expression eines CALM/AF10 Fusionproteins in primären Knochenmarkszellen ist  hochgradig 
leukämogen im Maus-Transplantationsmodell, da nach einer sehr kurzen Latenzzeit von nur 10 Wochen 
eine akuten Leukämie in den Mäusen diagnostizierbar ist.  
Ziel dieser Arbeit war es, bisher unbekannte, früher Zielgene des CALM/AF10-Fusionsproteins zu 
identifizieren. Dazu wurde das Fusions-Gen in den episomalen  pRTS-1 Vektor einkloniert, dessen 
Promotor mit Hilfe des Tetrazyklin-Derivats Doxyzyklin conditional  aktivierbar ist (Tet-on System). 
Dieses Kontrukt wurde dann in die Burkitt-Lymphomzelllinie DG75 stabil transfiziert und die Expression 
von CALM/AF10 nach Induktion des Vektors  mittels RT-PCR überprüft. Als Negativkontrolle dienten 
DG75 Zellen, die mit einem pRTS-1 Vektor ohne Fusionsgen stabil transfiziert worden waren. Mit Hilfe 
des Genchips Affymetrix® hgU133 plus 2.0 wurden Genexpressionsprofile erstellt. Um zwischen frühen 
und späten effekten der CALM/AF10 Expression unterscheiden zu können, wurden Genchipanalysen zu 
unterschiedlichen Zeitpunkten (24h und 72h nach Vektorinduktion) durchgeführt.  
Die statistische Datenanalyse des Genexpressionsprofil  wurde mit Hilfe der Software "R" und der dCHip 
Software durchgeführt und ergab folgende Ergebnisse: 24 Stunden nach der Induktion von CALM/AF10 
hatte sich  das Expressionsniveau von 1237 Genen um mindestens das 2 fache des Ausgangswertes 
verändert. Bei 594 Genen (=48%)  erniedrigte sich das Expressionniveau, im Gegensatz zu 643 Genen 
(=52%), deren Expressionsniveau sich erhöhte.  Unter den Genen, deren Expressionniveau sich erniedrigte, 
fanden sich Schlüsselgene der DNA-Reparatur (DDB2, TOP2A, BRCA1), der Zellzykluskontrolle (CCNE2, 
CHEK1, CDC2) und der Chromosomen-Stabilität (MCM3, MCM7, MCM10). Hochregulierte Gene 
kodierten für Signaltransduktionsmoleküle wie RAB8B (ein Mitglied der RAS Onkogen-Familie), 
Chromatin-Remodelling Faktoren wie BAZ2A (bromodomain adjacent to zinc finger domain, 2A), (STAT-
Familienmitglieder (STAT1 und STAT2) und MAML3 (mastermind like 3), das den Notch-Signalweg positiv 
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reguliert. Die Einordnung der differenziert regulierten Gene in Signalwegskaskaden mittels KegArray 
zeigte eine Anreicherung der differentiell regulierten Gene im Kategorien wie "Zellzyklusregulation" und 
"DNA-Replikation und Reparatur". Einen Anstieg des Expressionsniveaus der Hox Gene konnte jedoch 
nicht beobachtet werden, obwohl dies zuvor in einer Patientenstudie gefunden wurde (Dik et al., 2005). Zur 
Verifizierung der gefundenen Ergebnisse wurden die Veränderungen im Expressionsniveau einiger zuvor 
ausgewählter Gene mittels Taqman® Low Density Array (LDA) bestätigt. Dabei zeigte sich eine 
statistisch-signifikante Korrelation (r = 0.78, p = 0.001) zwischen den Realtime-PCR-Ergebnissen und den 
mittels Affymetrix-Array ermittelten Veränderungen im Expressionsniveaus der einzelnen Gene. Eine 
Gene Set Enrichment Analyse zeigte zudem, dass Gene, die bei der DNA-Reparatur und der genomischen 
Stabilität eine Rolle spielen, sowohl bei bei den deregulierten Genen in unserem Zellliniensystem als auch 
bei den differentiell regulierten Genen bei CALM/AF10-positiven Patienten signfikant überrepräsentiert 
sind.  Zusammenfassend zeigen unsere Untersuchungen, dass die Expression des leukämogenen 
Fusionsproteins CALM/AF10 zu einer starken Deregulierung von Schlüsselgenen in kritischen, zellulären 
Prozessen führt, und wir konnten somit erste Kandidaten-Gene für frühe Zielgene des CALM/AF10 
Fusionsproteins ermitteln.  
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VII. Appendix 
A1. Data obtained for Kill Curve Analysis (KCA) 
Concentration (µg) Percent Survival after 5 days Reference total 
.50 75.00 100.00 
.50 70.00 100.00 
.50 73.00 100.00 
.60 55.00 100.00 
.60 60.00 100.00 
.60 58.00 100.00 
.70 44.00 100.00 
.70 48.00 100.00 
.70 45.00 100.00 
.80 30.00 100.00 
.80 32.00 100.00 
.80 34.00 100.00 
.90 10.00 100.00 
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.90 5.00 100.00 
.90 5.00 100.00 
1.00 3.00 100.00 
1.00 4.00 100.00 
1.00 4.00 100.00 
 
 
A2. Test of Normality of the data using K-S (Kolmogorov-Smirnov) test. 
One-Sample Kolmogorov-Smirnov Test Concentration (µg/ml) 
Description Statistic 0.5 0.6 0.7 0.8 0.9 1 
Normal Parameters(a,b) Mean 72.66 57.66 45.66 32 6.66 3.66 
Std. Deviation 2.51 2.51 2.08 2 2.88 0.57 
Most Extreme Differences Absolute 0.21 0.21 0.29 0.17 0.38 0.38 
Positive 0.18 0.18 0.29 0.17 0.38 0.28 
Negative -0.21 -0.21 -0.21 -0.17 -0.28 -0.38 
Kolmogorov-Smirnov Z 0.37 0.37 0.5 0.3 0.66 0.66 
Asymp. Sig. (2-tailed) 0.99 0.99 0.95 0.99 0.76 0.76 
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A3. Result of ANOVA of different concentrations of puromycin kill-efficiency 
 
 Mortality Sum of Squares df Mean Square F Sig. 
Between Concentrations 11484.94 5 2296.99 464.56 .000 
Within Concentrations 59.33 12 4.94   
Total 11544.28 17    
 
  
A4. Independent comparison of different concentrations showing that increment in concentration of 
puromycin yielded significant increment in percentage of dead cells, except for the increment from 0.9 
to 1 µg. 
 
Concentration (µg) 
N Subset for alpha = .05 
1 2 3 4 5 1 
.50 3 27     
.60 3  42    
.70 3   54   
.80 3    68  
.90 3     93 
1.00 3     96 
Sig.  1.00 1.00 1.00 1.00 .58 
 
Means for groups in homogeneous subsets are displayed. 
a  Uses Harmonic Mean Sample Size = 3 
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A5. Calculated/estimated Probit Analysis model based on the mortality data collected 
      95% Confidence Interval 
  Parameter Estimate   Std. 
Error 
Z Sig. Lower 
Bound 
Upper 
Bound 
PROBIT(a) Concentration 
(ng) 
13.17 1.32 9.97 .00 10.58 15.76 
  Intercept -37.86 3.89 -9.74 .00 -41.75 -33.98 
 
PROBIT model: PROBIT(p) = Intercept + BX (Covariates X are transformed using the base 10 logarithm.)  
 
 
A6. Estimated kill probability (probit) for different puromycin concentration levels based on the 
mortality data collected. 
 
  Probability 95% Confidence Limits for 
Concentration (ng) 
95% Confidence Limits for 
log(Concentration (ng))(a) 
Estimate Lower 
Bound 
Upper 
Bound 
Estimate Lower 
Bound 
Upper 
Bound 
PROBIT(b) .010 500.035 411.157 562.288 2.699 2.614 2.750 
.020 524.449 438.222 584.218 2.720 2.642 2.767 
.030 540.553 456.297 598.592 2.733 2.659 2.777 
.040 552.993 470.375 609.648 2.743 2.672 2.785 
.050 563.323 482.140 618.800 2.751 2.683 2.792 
.060 572.267 492.380 626.705 2.758 2.692 2.797 
.070 580.226 501.533 633.724 2.764 2.700 2.802 
.080 587.446 509.868 640.081 2.769 2.707 2.806 
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.090 594.091 517.566 645.922 2.774 2.714 2.810 
.100 600.274 524.751 651.350 2.778 2.720 2.814 
.150 626.564 555.535 674.362 2.797 2.745 2.829 
.200 648.277 581.220 693.306 2.812 2.764 2.841 
.250 667.504 604.139 710.054 2.824 2.781 2.851 
.300 685.255 625.424 725.515 2.836 2.796 2.861 
.350 702.126 645.742 740.227 2.846 2.810 2.869 
.400 718.519 665.545 754.562 2.856 2.823 2.878 
.450 734.743 685.175 768.816 2.866 2.836 2.886 
.500 751.068 704.921 783.260 2.876 2.848 2.894 
.550 767.755 725.052 798.178 2.885 2.860 2.902 
.600 785.091 745.841 813.906 2.895 2.873 2.911 
.650 803.420 767.582 830.891 2.905 2.885 2.920 
.700 823.200 790.616 849.781 2.916 2.898 2.929 
.750 845.093 815.364 871.592 2.927 2.911 2.940 
.800 870.157 842.430 898.035 2.940 2.926 2.953 
.850 900.312 872.949 932.179 2.954 2.941 2.969 
.900 939.742 909.794 980.352 2.973 2.959 2.991 
.910 949.522 918.507 992.806 2.978 2.963 2.997 
.920 960.262 927.921 1006.674 2.982 2.968 3.003 
.930 972.211 938.230 1022.313 2.988 2.972 3.010 
.940 985.733 949.713 1040.248 2.994 2.978 3.017 
.950 1001.383 962.802 1061.286 3.001 2.984 3.026 
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.960 1020.089 978.206 1086.773 3.009 2.990 3.036 
.970 1043.565 997.240 1119.218 3.019 2.999 3.049 
.980 1075.610 1022.798 1164.216 3.032 3.010 3.066 
.990 1128.126 1063.886 1239.456 3.052 3.027 3.093 
a  Logarithm base = 10. 
b  A heterogeneity factor is used. 
 
A7. Gene list and fold regulation (LDA and affymetrix) 
Gene LDA Affy 
MLF1 28.33257 4.525701 
OAS1 28.17326 5.604744 
IFI6 27.99181 4.231276 
IFI44L 21.87256 5.252087 
CDC2 17.95673 3.569363 
DHRS2 17.84711 3.650866 
UNC13C 16.83723 3.665108 
BCL2A1 16.79263 3.633611 
CKS1B 16.21683 3.370275 
OAS2 16.19548 3.287767 
CDKN3 15.61251 3.681336 
DNAJB1 14.01363 3.180718 
HOXD10 13.82583 2.881668 
TREX1 13.78496 3.351746 
BIRC5;EPR1 13.76273 3.271797 
LY9 13.38118 2.79076 
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CCNB1 13.10304 3.242981 
STAT1 12.89233 3.597469 
RAP1A 12.89008 3.33826 
ANKRD39 12.76305 2.962647 
DDB2 11.99111 2.063714 
BIRC4BP 11.95635 3.26541 
ETV6 11.93008 2.786431 
JMJD1A 11.86804 2.920787 
CDCA3 11.5734 2.970424 
OTOF 11.22087 4.623846 
MZF1 10.96904 2.787606 
SEPP1 10.94182 2.468817 
CDC6 10.91783 3.035429 
IRX5 10.88233 2.824842 
SUV39H1 10.63244 2.76463 
HBP1 10.50044 2.702757 
SPBC24 10.48712 3.017905 
MCM10 10.30153 2.881917 
BCL2 10.26461 3.25085 
JMJD2B 10.25509 2.732236 
ETV7 10.15794 2.881668 
FHL2 10.15794 2.881668 
HOXB3 10.15794 2.881668 
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HOXD13 10.15794 2.881668 
PBX1 10.15794 2.846048 
PTN 10.15794 2.881668 
RAB8B 10.15794 2.881668 
WNT3 10.15794 2.507769 
CDC25C 9.973241 2.933275 
DNAJB9 9.756624 2.87052 
RECQL5 9.693124 2.667386 
MAML3 9.544616 2.854931 
CCNF 9.529396 2.631359 
TSGA10 9.517653 2.920866 
METT10D 9.460456 2.690977 
JMJD2C 9.414562 2.618284 
RAD51 9.293371 2.677388 
NEK2 9.236538 2.829051 
RAD51AP1 9.216778 2.860128 
PBXIP1 (HPIP) 7.59870 10.202341 
SMAD2/3 2.43180 9.546690 
SKP2 9.189228 2.69633 
FHL1 9.15025 3.21343 
USP18 9.08962 3.175629 
SKIL 9.073743 2.612052 
CREM 8.990205 2.726596 
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KIF23 8.650458 2.885807 
IFI27 8.543739 2.089735 
MAP4K3 8.524462 2.70185 
CHEK1 8.514601 2.706704 
MLL3 8.4914 2.621705 
BRCA1 8.486075 2.62364 
PBX2 8.477455 2.800326 
RMI1 8.447185 2.839224 
BRIP1 8.38464 6.569919 
ATM 8.367658 2.461272 
MYBL2 8.344836 2.480506 
ESPL1 8.32113 2.565788 
CASC5 8.271757 2.521866 
STAT2 8.224094 2.613837 
TOP2A 8.215572 2.277137 
CENPE 8.178639 2.624413 
CCNE2 8.048637 2.69551 
FOXP1 8.036818 2.616995 
RUNX1 7.862116 2.470978 
HELLS 7.837011 2.388881 
DNMT3B 7.694172 2.575032 
RARA 7.615044 2.482983 
UHRF1 7.476315 2.4227 
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MLL5 7.364065 2.461649 
CHAF1B 7.299285 2.490731 
TLX2 7.157793 2.456056 
BAZ2A 7.151682 2.400109 
SUV39H2 7.065186 2.363607 
MYBL1 6.937232 2.546511 
BCL2L11 6.84793 2.359521 
CHAF1A 6.461873 2.379459 
TCF7 5.285275 2.175603 
CDCA8 1.32764 1.128068 
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